Investigation of the mechanisms terminating growth factor induced Ras activation by Hennig, Anne
  
 
 
Investigation of the mechanisms terminating 
growth factor induced Ras activation 
 
Dissertation 
To Fulfill the Requirements for the Degree of 
"doctor rerum naturalium" (Dr. rer. nat.) 
 
 
 
 
 
 
 
 
 
 
 
 
Submitted to the Council of the Faculty of Biology and Pharmacy 
of the Friedrich Schiller University Jena 
 
 
 
 
 
 
 
by Anne Hennig  
(Dipl. Troph.) 
born on 11.11.1987 in Nordhausen 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gutachter: 
 
1. PD Dr. Ignacio Rubio, Friedrich-Schiller-Universität Jena 
2. Prof. Dr. Stefan Lorkowski, Friedrich-Schiller-Universität Jena 
3. Prof. Dr. Reinold Schäfer, Charité - Universitätsmedizin Berlin 
 
Tag der öffentlichen Verteidigung: 30.05.2016 
 Table of Content 
1 LIST OF FIGURES ......................................................................................................... I 
2 LIST OF TABLES..........................................................................................................III 
3 LIST OF ABBREVIATIONS ......................................................................................... IV 
4 ABSTRACT ................................................................................................................... 1 
5 ZUSAMMENFASSUNG................................................................................................. 2 
6 INTRODUCTION ........................................................................................................... 4 
6.1 Signal Transduction ......................................................................................... 4 
6.2 Ras a small GTPase ......................................................................................... 4 
6.2.1 Ras a bimolecular switch ........................................................................................... 5 
6.2.2 Structure of Ras ......................................................................................................... 7 
6.2.3 Post-Translational Modification of Ras ....................................................................... 9 
6.3 Regulators of the small GTPase Ras ............................................................ 10 
6.3.1 Guanin nucleotide exchange factors (GEFs) of Ras..................................................10 
6.3.2 GTPase activating proteins (GAPs) of Ras ...............................................................13 
6.4 Ras signalling ................................................................................................. 17 
6.4.1 Activation of Ras by receptor tyrosine kinases ..........................................................17 
6.4.2 Ras downstream effector signalling ..........................................................................18 
6.5 Ras signalling in tumourigenesis ................................................................. 20 
6.6 Ras feedback mechanism and negative regulator in Ras signalling ......... 22 
7 AIM OF THE WORK .....................................................................................................26 
8 MATERIALS AND METHODS .....................................................................................27 
8.1 Material............................................................................................................ 27 
8.1.1 Reagents ..................................................................................................................27 
8.1.2 Buffers and solutions ................................................................................................28 
8.1.3 Antibodies .................................................................................................................30 
8.1.4 Inhibitors ...................................................................................................................31 
8.1.5 siRNA .......................................................................................................................31 
8.1.6 Real-time qPCR primer .............................................................................................31 
8.1.7 Plasmids ...................................................................................................................32 
8.1.8 Kits ...........................................................................................................................32 
  
 8.2 Methods .......................................................................................................... 32 
8.2.1 Cell line and stimulations ..........................................................................................32 
8.2.2 Transfection of cell lines ...........................................................................................33 
8.2.3 RNA isolation, cDNA synthesis and quantitative real-time PCR analysis ..................34 
8.2.4 SDS-PAGE ...............................................................................................................35 
8.2.5 Western Blotting and immunodetection of immobilised proteins ................................35 
8.2.6 Expression and purification of the Raf-1-Ras binding domain ...................................36 
8.2.7 Ras activity assay .....................................................................................................37 
8.2.8 Nucleotide exchange assay and Ras immunoprecipitation .......................................38 
8.2.9 Thin layer chromatography .......................................................................................38 
8.2.10 Mathematical modelling ........................................................................................39 
8.2.11 Nanocluster assay ................................................................................................39 
9 RESULTS .....................................................................................................................41 
9.1 EGF induces transient Ras activation .......................................................... 41 
9.2 Mathematical model describing the feedback stimulation of GAP activity43 
9.3 EGF mediates sequential engagement of Sos ............................................. 45 
9.3.1 Sos is phosphorylated downstream of Ras ...............................................................45 
9.3.2 Sos activity does not decay with decline in RasGTP levels .......................................45 
9.4 A feedback mechanism limits the duration of Ras activation .................... 49 
9.4.1 Inhibition of MEK and Erk prolongs RasGTP level ....................................................49 
9.4.2 Inhibition of Rsk also leads to prolonged RasGTP accumulation ..............................50 
9.4.3 PI3K/Akt and p38 inhibition do not influence the transient Ras kinetics .....................52 
9.5 Sos activity is not affected by the feedback mechanism ........................... 52 
9.6 NF1 is the responsible GAP within the feedback loop................................ 53 
9.6.1 siRNA mediated NF1 knockdown prolongs RasGTP accumulation ...........................55 
9.6.2 NF1 acts in a background of high nucleotide exchange activity ................................56 
9.7 NF1 harbours conserved Erk and Rsk phosphorylation sites ................... 57 
9.8 Spred proteins and Ubiquitin are possible NF1 interaction partners ........ 59 
9.9 MEK inhibition increases Ras nanoclustering ............................................ 61 
9.10 Modelling of a GAP-mediated feedback ....................................................... 62 
9.10.1 Late time GAP blockade via Erk inhibition .............................................................62 
9.10.2 Late time GEF blockade via EGFR inhibiton .........................................................63 
  
 10 DISCUSSION ...............................................................................................................65 
10.1 Ras activation is of transient nature ............................................................ 66 
10.2 Sos phosphorylation does not reduce nucleotide exchange activity on 
Ras .................................................................................................................. 68 
10.3 Ras deactivation is driven by Rsk-dependent feedback activation ........... 70 
10.4 NF1 in the agonist-dependent control of Ras deactivation ........................ 71 
10.4.1 Direct NF1 phosphorylation as possible regulation mechanism .............................72 
10.4.2 NF1 regulation via unknown intermediate proteins ................................................72 
10.4.3 EGF dependent NF1 and Ras distribution .............................................................75 
10.5 Combination of biological data and mathematic modelling ....................... 77 
10.6 Clinical Relevance of Rsk dependent NF1 activation ................................. 79 
10.7 Concluding remarks ...................................................................................... 80 
11 REFERENCES .............................................................................................................. A 
12 DANKSAGUNG ............................................................................................................ T 
13 EHRENWÖRTLICHE ERKLÄRUNG ............................................................................. U 
14 CURRICULUM VITAE ................................................................................................... V 
LIST OF FIGURES | I 
1 List of figures 
Figure  1: The Ras cycle by GEF and GAP proteins. ................................................. 7 
Figure  2: Structure of Ras .......................................................................................... 8 
Figure  3: Overview of Ras post-translational modification and membrane                            
trafficking within the cell compartments. .................................................. 10 
Figure  4: Domain structure of the RasGEF classes. ................................................ 12 
Figure  5: Domain architecture of RasGAPs. ............................................................ 15 
Figure  6: Ras activates multiple downstream effector pathways ............................. 20 
Figure  7: Overview of the main developmental disorders and tumours                       
associated with aberrant Ras signalling. .................................................. 22 
Figure  8: Possible Ras feedback mechanisms. ....................................................... 25 
Figure  9: Coomassie stained SDS-PAGE of fractions from RBD purification. ......... 36 
Figure 10: Comparison of the applied assays. .......................................................... 37 
Figure 11: EGF induces transient Ras activation. ..................................................... 42 
Figure 12: Mathematical model and basal GAP activity ........................................... 44 
Figure 13: EGF induces a mobility shift in Sos. ........................................................ 45 
Figure 14: EGF induces transient RasGTP accumulation and prolonged                                
up-regulation of nucleotide exchange. ..................................................... 48 
Figure 15: GppNHp but not GTP promotes strong Ras activation at late time                       
points of EGF stimulation. ........................................................................ 49 
Figure 16: Inhibition of the MEK/Erk pathway prolongs Ras activation. .................... 50 
Figure 17: Rsk inhibition leads to RasGTP accumulation at late EGF stimulation                
time point. ................................................................................................ 51 
Figure 18: EGF induces PI3K and p38 independent transient Ras activation. ......... 52 
Figure 19: Feedback deactivation of Ras is mediated via GAP up-regulation. ......... 53 
Figure 20: Immunoblot detection and GEO search for GAP protein expression in 
HeLa cells ................................................................................................ 54 
Figure 21: Feedback mediated stimulation of NF1 mediates Ras deactivation. ....... 56 
Figure 22: NF1 activation mediated Ras deactivation .............................................. 57 
Figure 23: Multiple sequence alignment of NF1 proteins from different species ....... 59 
LIST OF FIGURES | II 
Figure 24: Spred2 overexpression reduces RasGTP levels and nucleotide             
exchange activity. .................................................................................... 60 
Figure 25: Loss of MEK activity alters H-Ras nanoclustering. .................................. 62 
Figure 26: Late time Erk inhibition blocks the GAP activity and increases the           
RasGTP level. .......................................................................................... 63 
Figure 27: Late time EGFR inhibition blocks the GEF activity and decrease the 
RasGTP level. .......................................................................................... 64 
Figure 28: Ras activation/deactivation can occur via changes in GEF and/or                   
GAP activity. ............................................................................................ 66 
Figure 29: Possible mechanisms to initialise the decline of RasGTP levels. ............ 76 
Figure 30: Mathematical model describing the feedback stimulation of GAPs. ........ 78 
Figure 31: Schematic cartoon of the mechanism of Ras activation/deactivation. ..... 78 
LIST OF TABLES | III 
2 List of tables 
Table 1: List of reagents ........................................................................................... 27 
Table 2: Buffers for Sodium Dodecyl Sulfate - Polyacrylamide Gel Electrophoresis 28 
Table 3: Buffers for Western blotting and immunodetection ..................................... 28 
Table 4: Buffer for Ras activity assay ....................................................................... 29 
Table 5: Buffers for Nucleotide exchange assay ...................................................... 29 
Table 6: Buffer for Nanocluster assay ...................................................................... 29 
Table 7: List of antibodies for western blot analyses ................................................ 30 
Table 8: List of inhibitors ........................................................................................... 31 
Table 9: List of siRNAs ............................................................................................. 31 
Table 10: List of primers ........................................................................................... 31 
Table 11: List of plasmids ......................................................................................... 32 
Table 12: List of Kits ................................................................................................. 32 
Table 13: qRT-PCR Reaction Mix ............................................................................ 34 
Table 14: Western Blot transfer conditions ............................................................... 36 
Table 15: Studies documenting a stimulation of nucleotide exchange on Ras in  
permeabilised cells in response to growth factors and mitogens. ............ 68 
 
LIST OF ABBREVIATIONS | IV 
3 List of abbreviations 
Akt  protein kinase B 
BTK bruton tyrosine kinase 
Cpm counts per minute 
DAG diacylglycerin 
DH dbl homology 
EGF epidermal growth factor 
EGFR epidermal growth factor receptor 
EM electron microscopic 
ER endoplasmatic reticulum 
Erk extracellular-signal-regulated kinase 
GAP  GTPase activating protein 
GDP guanosine diphosphate 
GEF guanine nucleotide  exchange factor 
GppNHp guanosine-5’-[(β,γ)-imido]triphosphate 
Grb2 growth factor receptor-bound protein 2 
GST glutathione S-transferase 
GTP guanosine triphosphate 
hvr hyper variable region 
IP Immunoprecipitation 
IP3 inosit-1,4,5-trisphosphat 
MAPK  mitogen-activated protein kinase 
MEK mitogen/extracellular signal-regulated kinase  
mRNA messenger RNA 
MS mass spectrometry 
NF1 neurofibromin 1 
NGF nerve growth factor 
PH pleckstrin homology 
PI3K  phosphoinositide 3-kinase 
PIP2 phosphatidylinositol-4,5-bisphosphate 
PIP3 phosphatidylinositol-3,4,5-trisphosphate 
PKC protein kinase C 
PLC phospholipase Cε 
PLD1 phospholipase D1 
PM plasma membrane 
PR proline-rich 
RA Ras association 
Ras rat sarcoma 
RasGRF Ras guanine nucleotide releasing factor 
RasGRP Ras guanine nucleotide releasing protein 
RBD Ras binding domain 
REM Ras exchange motif 
Rsk ribosomal S6 kinase 
RT room temperature 
RTK receptor tyrosine kinase 
SH2/3 src homology 2/3 
siRNA small interfering RNA 
SLO streptolysin O 
Sos  son of sevenless 
STAT Signal Transducer and Activator of Transcription 
ABSTRACT | 1 
4 Abstract 
Transient Ras activation induced by growth factors is crucial for normal cell 
proliferation. Ras activity is regulated by opposing actions of two classes of Ras 
regulatory enzymes. Guanine nucleotide exchange factors (GEFs) promote  
GTP-bound Ras state by enhancing exchange of GDP with GTP. GTPase activating 
proteins (GAPs) enhance the otherwise slow intrinsic Ras GTPase activity rate, 
promoting conversion into the inactive GDP-bound state of Ras. The rise in RasGTP 
levels following exposure to growth factors is well understood. It proceeds via 
stimulation of Sos, a GEF which drives the accumulation of active, GTP-loaded Ras. 
The mechanism of the ensuing deactivation of Ras is not yet fully understood, but is 
inferred to involve feedback inhibition of Sos. This study focuses on understanding of 
how Ras signalling is terminated in the context of a mitogenic environment to limit 
and control Ras signalling in time.  
An experimental strategy involving cell permeabilisation enabled the loading of cells 
with radioactive [α-32P]GTP in order to monitor both the rate of [α-32P]GTP uptake as 
well as the [α-32P]GTP / [α-32P]GDP ratio on Ras at the pre-steady-state. Combining 
both pieces of information allowed important conclusions on GEF activity and the 
contribution of GAPs. The downstream activation of canonical Ras-MAPK signalling 
pathway was analysed by Western Blotting.  
It was observed that growth factors induce a characteristically transient Ras 
activation in HeLa cells. Strikingly, GEF activity is continuously high at all time points 
tested, even if RasGTP levels have dropped back to the basal state. Experiments 
with non-hydrolysable GTP analogues and mathematical modelling confirmed the 
presence of high GAP activity at late stages of growth factor stimulation. Finally we 
identified a crucial activation of the GAP protein NF1 to counteract GEF activity and 
to deactivate Ras. Furthermore, Rsk1/2 inhibition led to a sustained Ras activation 
whereas the GEF activity was not affected. Collectively, the findings emerged from 
this thesis identified a new molecular mechanism terminating growth factor induced 
Ras activation characterised by the involvement of Rsk and NF1 in a feedback loop. 
For the first time a biochemical stimulation of the GAP activity associated with growth 
factor signalling pathways was demonstrated.  Secondly, the acquired data revealed 
a central role of the tumour suppressor NF1 as an executing target protein of a 
MAPK induced feedback pathway. Prospectively it is of medical importance to figure 
out the biochemical link between Rsk and NF1 activation in growth factor induced 
Ras deactivation to improve therapeutic strategies for patients with RASopathy 
syndromes. 
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5 Zusammenfassung 
Transiente Ras-Aktivierung induziert durch Wachstumsfaktoren ist entscheidend für 
normale Zellproliferation. Ras-Aktivität wird durch entgegengesetzte Eigenschaften 
zweier Ras regulatorischer Enzyme kontrolliert. Die Guanin-Nukleotid-
Austauschfaktoren (GEFs) fördern dabei den GTP-gebundenen Zustand von Ras 
durch den beschleunigten Austausch von GDP mit GTP am Ras-Molekül. Die 
GTPase-aktivierende Proteine (GAPs) erhöhen die geringe intrinsische GTPase 
Aktivitätsrate, welches den inaktiven GDP-gebundenen Zustand fördert. Bei der  
Ras-Aktivierung, welche durch ein rasch ansteigendes RasGTP Level nach 
mitogener Stimulation gekennzeichnet ist, handelt es sich um ein im Detail 
verstandenen Mechanismus. Die Stimulation von Sos, einem GEF, treibt dabei die 
Ansammlung von aktivem GTP-beladenem Ras an. Der Mechanismus der 
anschließenden Ras-Deaktivierung ist hingegen noch nicht vollständig aufgeklärt. Es 
wird jedoch vermutet, dass eine Rückkopplungshemmung auf Sos involviert ist. Im 
Rahmen meiner Arbeit galt es zu verstehen, wie das Ras-Signal nach mitogener 
Stimulation herunterreguliert wird, um die Aktivierung der Ras-Signalwege zeitlich zu 
begrenzen und zu kontrollieren.  
Wir verwendeten eine Permeabilisierungstrategie, die es uns ermöglichte, Zellen mit 
radioaktivem [α-32P] GTP zu laden, um erstens die Rate der [α-32P] GTP-Aufnahme, 
und zweitens den [α-32P] GTP/[α-32P] GDP Quotienten von Ras im pre-steady-state, 
zu verfolgen. Die kombinierte Betrachtung der beiden Informationen erlaubt 
Rückschlüsse auf die GEF-Aktivität und den Beitrag der GAPs. Die Aktivität des 
kanonischen Ras-MAPK-Signalweges wurde mittels Western Blot analysiert. 
Wir beobachteten, dass Wachstumsfaktoren eine charakteristische transiente  
Ras-Aktivierung in HeLa Zellen induzieren. Erstaunlicherweise war die GEF-Aktivität 
zu jeder Zeit konstant hoch, auch wenn die RasGTP Level bereits wieder auf 
Grundniveau zurückgegangen waren. Experimente mit nicht-hydrolysierbaren  
GTP-Analoga und mathematische Modellierung bestätigten und rationalisierten die 
Anwesenheit von hoher GAP-Aktivität in den späten Phasen der hormonellen 
Stimulation. Wir zeigten eine Aktivierung des GAP-Proteins NF1, um der  
GEF-Aktivität entgegenzuwirken und Ras zu deaktivieren. Darüber hinaus führte eine 
Rsk1/2 Hemmung zu einer anhaltenden Ras-Aktivierung, wobei die GEF-Aktivität 
jedoch nicht beeinflusst wurde. Zusammenfassend zeigen unsere Ergebnisse einen 
neuartigen molekularen Mechanismus zur Regulation des mitogen aktivierten, 
transienten Ras-Signals gekennzeichnet durch die Beteiligung von Rsk und NF1 
innerhalb einer Rückkopplungsschleife.  
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Wir konnten somit erstmalig einerseits eine Stimulation der GAP Aktivität im 
Zusammenhang mit Wachstumsfaktorsignalwegen demonstrieren und 
dokumentieren. Andererseits enthüllen diese Daten eine zentrale Rolle des 
Tumorsuppressors NF1 als ausführendes Zielprotein von MAPK-induziertem 
Rückkopplungssignalweg. Prospektiv ist es von medizinischer Bedeutung die 
biochemische Verbindung zwischen Rsk und NF1-Aktivierung in Wachstumsfaktor-
induzierter Ras Deaktivierung herauszufinden, um die Therapiestrategien für 
Patienten mit RASopathy Syndromen zu verbessern. 
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6 Introduction 
6.1 Signal Transduction 
Cells communicate with each other through extracellular signalling molecules or  
cell-cell contacts. In this manner cells coordinate physiological multi-cellular 
processes such as proliferation, differentiation, migration, survival, and apoptosis. 
Cytokines, growth factors, and hormones are so called chemical messengers and 
transmit messages between the cells. Not all molecules can pass through the lipid 
bilayer of a cell, and so signal transduction systems are used in order to relay an 
external signal to the cell interior.  
Typically, cellular signalling cascades involve phosphorylation events through various 
kinases that lead to a large amplification of the signal and finally activate an effector 
or regulatory protein and consequently regulate cellular functions. These enzymatic 
cascades are tightly controlled in order to prevent disastrous consequences for 
proper cell functioning. The stimulating signal that initiates a cellular response 
routinely also initiates a mechanism for shutting down that response. For example, 
the activation of a kinase often triggers the activation of a corresponding 
phosphatase. 
Its important to understand signalling networks since mutations in genes, which 
encode for proteins involved in signal transduction, are enriched in malignant cells 
and tumours. Generally, an extracellular signal activates many different signal 
transduction pathways that lead to a number of cellular responses, in this work we 
focus on the growth factor induced Ras signalling pathways. 
6.2 Ras a small GTPase 
Ras is a key regulator in various signal transduction pathways and ensures survival 
of the cell through its involvement in cellular proliferation, differentiation, apoptosis 
and cytoskeletal reorganisation (Hall, 1990a, Crespo and Leon, 2000). 
Beside heterotrimeric G proteins, small GTPases are a type of G-Proteins. The Ras 
superfamily of small GTPases comprises over 150 human members and exhibit 
5 subfamilies: Ras, Rho, Rab, Arf and Ran (Takai et al., 2001, Colicelli, 2004b, 
Wennerberg et al., 2005). All GTPases are molecular switches that alternate between 
an active GTP bound state and an inactive GDP bound state.  
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Arf family proteins play a role in vesicular transport (Nie et al., 2003) and members of 
the Rho family regulate organelle development, cytoskeletal dynamics and cellular 
movement (Burridge and Wennerberg, 2004). Rab GTPases regulate the intracellular 
vesicle transport (Stenmark and Olkkonen, 2001) whereas Ran proteins control 
nuclear transport systems (Dasso, 2006).  
The best-studied members of the Ras GTPases are Harvey-Ras (H-Ras),  
Kirsten-Ras (K-Ras), and neuroblastoma-Ras (N-Ras). They have a molecular weight 
of 20 to 25 kDa and control various cellular functions such as cell proliferation, cell 
differentiation, and cell death (Shimizu et al., 1983, Colicelli, 2004a). The three Ras 
isoforms were firstly discovered as transforming oncogenes of murine sarcoma 
viruses (DeFeo et al., 1981) and later identified in eukaryotes from yeast to humans. 
All isoforms are highly related, sharing approximately 85% protein identity  (Barbacid, 
1987), whereas the major variability exist in the carboxyl terminus. Ras proteins are 
expressed ubiquitously in mammalian cells and display biologically significant 
differences despite their high degree of homology: K-Ras is essential for normal 
mouse embryogenesis (Johnson et al., 1997, Koera et al., 1997, Esteban et al., 
2001), whereas H- and N-Ras double knockout mice were shown to be viable 
(Umanoff et al., 1995). Studies in so-called Rasless MEFs (carrying null H‐Ras and 
N‐Ras alleles along with a floxed K‐Ras) illustrate that the Ras isoforms are essential 
for proliferation and migration, but not for survival. Further they showed that the 
activation of the Raf/MEK/Erk pathway but not the PI3K pathway was sufficient to 
sustain normal proliferation and migration in Rasless MEFs (Drosten et al., 2010). In 
this thesis, we will not differentiate between the Ras isoforms, so the term Ras will be 
used for all three Ras isoforms collectively. 
6.2.1 Ras a bimolecular switch 
Ras proteins are essential for cells to leave a quiescent state (G0) as well to pass 
through the G1/S transition of the cell cycle (Taylor and Shalloway, 1996, Peeper et 
al., 1997, Crespo and Leon, 2000). Thus, Ras proteins show two peaks of activation 
during the cell cycle. The first Ras activation during G1 phase progression is transient 
(Marshall, 1995a, Coleman et al., 2004) whereas the second Ras activation in cycling 
cells at mid-G1 is prolonged (Dobrowolski et al., 1994, Taylor and Shalloway, 1996). 
The latter is uncoupled from Erk activation and is dependent on RNA and protein 
synthesis (Taylor and Shalloway, 1996).  
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In conclusion, quiescent cells require at least two peaks of Ras activation in order to 
run through one round of cell division. Its still a debate if Ras targets other pathways 
in mid-G1 phase to push the progression into S phase, since functional links for Ras 
and the retinoblastoma tumour-suppressor protein (Rb) for G1 exiting has been 
suggested. In the present thesis we will only pay attention on the first short-lived Ras 
activation peak.  
The sequential steps for a Ras cycling between the active GTP-bound and inactive 
GDP-bound state are: 1) GTP binding, 2) GTP hydrolysis, 3) phosphate release, and 
4) GDP release. Thereby the rate-limiting step for Ras protein activation is the 
exchange of bound GDP with GTP. In the late 80s several groups measured the rate 
constants for the nucleotide dissociation step and in most cases this is a very slow 
step (around 4 x 10-4 s-1) (Neal et al., 1988). In contrast the Ras activation in the cell 
takes place within seconds to minutes after growth factor induced RTK stimulation. 
That means the intrinsic reaction rates of Ras are too slow for efficient Ras activation 
after stimulation and favouring an inactive steady state conformation of Ras even in 
the presence of a high cellular GTP/GDP ratio (Buday and Downward, 2008). The 
intrinsic GTPase activity (the rate limiting step for Ras inactivation) of Ras is also low 
(4.2 x 10−4 s−1), which would tend to prolonged signal transduction (Neal et al., 1988). 
Obviously, Ras kinetics is modified by two classes of auxiliary proteins namely GEFs 
and GAPs (Figure 1).  
RasGTP accumulation is triggered by GEF binding. The GEF catalysed release of 
GDP will be immediately followed by the rapid binding of GTP, just because GTP is 
abundant in the cell (10fold higher) relative to GDP (Vetter and Wittinghofer, 2001). 
EGFR signalling requires the recruitment of Sos (a prominent RasGEF) to the plasma 
membrane in order to induce Ras activation which is manly assisted by adaptor 
proteins like Shc and Grb-2 (Buday and Downward, 2008). It is important to note that 
Ras activation is not exclusively the outcome of GEF activity (Hennig et al., 2015). 
There are further levels of Ras activation such as: 1) mono-ubiquitination, which 
possibly interfere with GAP function (Jura et al., 2006, Hobbs et al., 2013), 2) the 
movement of Ras molecules between raft and non-raft microdomains, which probably 
affect access of Ras for GEFs and GAPs (Prior et al., 2001) or 3) signalling 
molecules like nitric oxide or cyclopentenone prostaglandins, which directly modify 
specific cysteine residues of the C-terminal Ras region (Oliva et al., 2003, Heo et al., 
2005).  
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Ras inactivation is controlled by GAPs, which stimulate the low intrinsic GTPase 
activity thereby increasing the rate of GTP hydrolysis to GDP. In contrast to GEF 
mediated Ras activation, the molecular mechanisms of GAP activity and regulation 
upon mitogenic signalling are still a controversial topic.  
 
Figure 1: The Ras cycle by GEF and GAP proteins.  
Ras cycle between an active (GTP-bound) and inactive (GDP-bound) state controlled by GEFs and 
GAPs. GEFs stimulate the exchange of GDP for GTP, whereas GAPs bind to Ras and stimulate its 
intrinsic GTPase activity. 
6.2.2 Structure of Ras 
The potential of the molecular switch is based on two fundamental properties of Ras: 
1) Ras binds guanine nucleotides with high affinity and 2) Ras hydrolyses bound GTP 
to GDP and inorganic phosphate (Figure 1).  
The crystal structure of the Ras protein as well as its interactions with nucleotides 
was identified in the late 80s by Sung-Hou Kim (de Vos et al., 1988) and Alfred 
Wittinghofer (Pai et al., 1989, Wittinghofer and Pai, 1991). Ras contains a G-domain 
made of five conserved polypeptides loops (G1-G5) and a C-terminal CaaX box 
mediating interaction with a lipid bilayer (Figure 2). The G-Domain carries out basic 
functions of nucleotide binding and hydrolysis. In the GTP bound form the  
γ-phosphate of the GTP and two invariant amino acids of the switch I (G2 motif) and 
switch II (G3 motif) form two hydrogen bonds. The P-loop (G1) is a glycine-rich loop 
and binds the α/β-phosphate of the GTP as well as coordinates the divalent 
magnesium ion, which helps to coordinate nucleotide binding. G4 and G5 motif are 
responsible for the specific guanine binding with G4 carrying a guanine binding motif. 
As soon as a water molecule has been optimally positioned for nucleophilic attack on 
the γ-phosphate of GTP the switch regions relax which causes a conformational 
change and the hydrolysis of GTP (McCormick et al., 1985, Vetter and Wittinghofer, 
2001).  
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Since the GDP release is comparable slow this process is triggered via interaction 
with a Ras nucleotide exchange factor, mainly Sos. The Ras/Sos interaction takes 
place in the switch I and II region leading to a sterically displace of the magnesium 
ion which results in GTP binding. Then the GTP-bound conformation allows binding 
of downstream effectors (Vetter and Wittinghofer, 2001). 
 
Figure 2: Structure of Ras 
A) Crystallographic structure of H-Ras loaded with non-hydrolysable GTP is shown. G-domains are 
coloured. B) Schematic diagram of the Ras protein domains. The catalytic units G1-G5 are involved in 
GDP/GTP binding and the CaaX motif at the C-terminus is essential for membrane binding and 
trafficking. The most common oncogenic mutations occurred at codon 12, 13, and 61, the region that 
is identical among the 3 isoforms. Figure 2A adapted from (Hennig et al., 2015). 
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6.2.3 Post-Translational Modification of Ras 
The Ras proteins are membrane-associated proteins due to post-translational 
modifications, which add a hydrophobic anchor, a process that is required for Ras 
activation and signalling. The C-terminal CaaX motif undergoes sequentially  
post-translational modification by three enzymes: farnesyltransferase (FTase),  
Ras-converting enzyme 1 (RCE1) and isoprenylcysteine carboxylmethyltransferase 
(ICMT). First Ras gets prenylated, involving the transfer of either a farnesyl moiety to 
CaaX cystein in the cytosol that directs Ras to the endoplasmatic reticulum (ER) 
(Figure 3). Next the tripeptide aaX is cleaved from the C-terminus by the specific 
endoprotease RCE1 bringing the farnesylcysteine into the C-terminal position. The 
now C-terminal prenylcysteine of Ras is methylated by ICMT a methyltransferase 
(Choy et al., 1999, Wright and Philips, 2006) (Figure 3). N-Ras and H-Ras undergo 
an isoform specific palmitoylation step within the hyper variable region (hvr), a region 
of 20 amino acids upstream of the CaaX sequence, which enables a Golgi apparatus 
mediated vesicle transport to the plasma membrane (Hancock et al., 1990) (Figure 
3). In particular, we have previously shown that the palmitoylation of N-Ras is 
necessary for activation by agonists in growth factor signalling (Song et al., 2013). 
Conclusively, the recirculation to the Golgi and the ER, which is initiated by 
depalmitoylation, may contribute to the shutdown of Ras signalling. In contrast,  
K-Ras have two splice variants K-Ras4A and K-Ras4B. The latter one, which is not 
palmitoylated, displays a positively charged basic sequence with six contiguous 
lysines and traffic directly to the plasma membrane via a poorly understood pathway 
(Apolloni et al., 2000) (Figure 3). Mutations in the CaaX motif or loss of a modifying 
enzyme result in defective Ras processing and aberrant localisation of Ras within 
cells (Kim et al., 1999). 
Shown by our own group endogenous growth factor induced RasGTP is 
predominantly localised at the plasma membrane (Augsten et al., 2006). Here, Ras 
isoforms are not distributed randomly. Ras proteins are localised in plasma 
membrane domains, e.g. lipid rafts and caveolea. This distribution is Ras isoform 
specific (Abankwa et al., 2010). Especially, H-Ras is associated in microdomains with 
cholesterolrich regions (lipid rafts) whereas K-Ras operates from actin-dependent, 
cholesterol-independent nanoclusters (Prior et al., 2003) and N-Ras is a prominent 
endomembranous component.  
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Interestingly, segregation of GTP-bound H-Ras from rafts is essential for efficient Raf 
activation (Prior et al., 2001, Rotblat et al., 2004, Guzman et al., 2014). 
 
Figure 3: Overview of Ras post-translational modification and membrane trafficking within the 
cell compartments.  
CaaX processing is initiated in the cytosol by prenylation followed by proteolysis and a methylation 
step at the ER. K-Ras then traffics to the plasma membrane through a poorly characterised pathway. 
H-Ras and N-Ras, after palmitoylation pass the Golgi and reach the PM with the aid of vesicles. 
Depalmitoylated H-Ras and N-Ras cycle through the ER for repalmitoylation. 
6.3 Regulators of the small GTPase Ras 
The status of Ras activity is under the control of two major regulators GEFs and 
GAPs. This chapter of the thesis describes the structure, regulatory mechanisms of 
GEFs and GAPS as well as their involvement in human cancer or other 
malignancies.  
6.3.1 Guanin nucleotide exchange factors (GEFs) of Ras 
 
RasGTP formation results from the growth factor sparked stimulation of nucleotide 
exchange on Ras. This process is triggered by RasGEFs, which promote the 
dissociation of otherwise tightly bound nucleotides from Ras proteins.  
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Mammals express 3 classes of RasGEFs (Figure 4). The expression of the 2 GEF 
families RasGRF and RasGRP is largely restricted to neurons and leukocytes 
(Kawasaki et al., 1998, Dower et al., 2000, Pierret et al., 2000, Fernandez-Medarde 
and Santos, 2011b), whereas Ras activation in other cell types is mostly driven by 
the ubiquitously expressed GEF Sos. There are 2 known members of the mammalian 
Sos family (Sos1 and Sos2). Upon growth hormone receptor stimulation, Sos that is 
normally cytoplasmic, gets recruited to the plasma membrane thereby reaching the 
vicinity of Ras. To achieve this, the PH domain of Sos serves a membrane-targeting 
function (Chen et al., 1997) and the C-terminal proline-rich (PR) region serves as the 
recognition site for SH3 domains on Grb2 to mediates their interaction (Rozakis-
Adcock et al., 1993).  
In general GEFs are multidomain proteins (Bos et al., 2007) (Figure 4). The REM 
(Ras exchange motif) and cdc25 domain form the catalytic module and are common 
to almost all Ras-family GEF structures. The Dbl homology (DH) /pleckstrin homology 
(PH) domains in tandem, binds Ras and opens it for GDP/GTP exchange (Soisson et 
al., 1998). The PH and C1 domains are responsible for lipid binding, whereas IQ and 
EF domains facilitate calcium binding. Due to those putative calcium-binding 
properties, second messengers like DAG and Ca2+ and their role in Ras activity have 
been discussed extensively (Farnsworth et al., 1995, Ebinu et al., 1998, Cullen and 
Lockyer, 2002, Walker et al., 2003). Indeed the calcium-binding on the EF module 
plays a crucial role in stimulating RasGRP1 activity (Iwig et al., 2013). Furthermore 
the DAG binding C1 domain is mandatory to recruit the RasGRPs to the plasma 
membrane in order to activate Ras (Ebinu et al., 1998, Johnson et al., 2007).  
Sos is able to induce GDP/GTP exchange on all 3 Ras isoforms. Upon growth factor 
stimulation, Sos is recruited by Grb2 to the plasma membrane and activate Ras 
(Aronheim et al., 1994). Once Sos is activated, the interaction of the REM domain 
with the switch 2 region of Ras mediates the anchoring to RasGDP, whereas the 
interaction of the cdc25 domain with the switch 1 region of Ras leads to GDP 
dissociation (Rojas et al., 2011). 
There are diverse regulatory mechanisms of Sos activity (Cherfils and Zeghouf, 
2013). Under resting conditions in the cytosol, Grb2 provokes negative regulation 
and so reduces the stimulus-independent Ras activation (Zarich et al., 2006).  
In addition the DH-PH unit is a autoinhibitory domain and block the allosteric binding 
site for Ras (Sondermann et al., 2004).  
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It is also described that the binding of phospholipase D2 generated phosphatidic acid 
to the PH-domain of Sos is necessary for the localisation of Sos to the membrane 
and activation of Ras (Zhao et al., 2007, Litosch, 2015).  
 
Figure 4: Domain structure of the RasGEF classes.  
The REM-cdc25 tandem module harbours the catalytic domain that exhibits nucleotide exchange 
activity towards Ras. Domain nomenclature according to SMART database (http://smart.embl-
heidelberg.de/): C1, DAG-binding C1 domain; cdc25, catalytic GEF domain; DH, Dbl homology; EF, 
Ca2+-binding EF hand; IQ, calmodulin-binding motif; HD, histone domain; HL, helical linker; PH, 
Pleckstrin homology; PR, proline-rich region; REM, Ras exchanger motif. Figure based on (Hennig et 
al., 2015). 
GEFs in malignancies 
Mutational activation of the RasGEF Sos has been identified in human genetic 
syndromes such as the Noonan syndrome, which is characterised by short stature, 
facial dysmorphia, congenital heart defects and skeletal anomalies (Tartaglia et al., 
2007, Pierre et al., 2011). Noonan syndrome is an autosomal dominant disorder that 
frequently shows mutations in PTPN11 (Tyrosine-protein phosphatase non-receptor 
type 11) and in several members of the Ras/Erk pathway such as K-RAS and RAF 
(Roberts et al., 2007, Shannon and Bollag, 2007). PTPN11 mutations are mostly 
missense mutations and lead to increased Ras/Erk pathway activity (Ostman et al., 
2006). Additional a mutation in the SOS1 gene causes hereditary gingival 
fibromatosis type 1 (Hart et al., 2002) (Figure 7). Further ablation of Sos1 in mice is 
embryonic lethal (Qian et al., 2000, Baltanas et al., 2013) and cannot be 
compensated by Sos2 (Qian et al., 2000). Many germline mutations are located in 
the amino-terminal region (HD, DH, PH, HL) of Sos and perturb intramolecular 
interactions, which are necessary for Sos autoinhibition (Sondermann et al., 2004). 
Aberrant RasGRP1 and 4 activities are reported in leukemogenesis and the 
overactive RasGRP3 is involved in the formation and maintenance of prostate 
cancer. Overexpression of RasGRP3 is also observed in human breast tumour tissue 
samples as well as in multiple human breast cancer cell lines (Ksionda et al., 2013). 
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6.3.2 GTPase activating proteins (GAPs) of Ras 
The human genome predicts 170 GAPs for small GTPases, of which only 6 classes 
are bona fide RasGAP proteins (Bernards, 2003, Bos et al., 2007) (Figure 5).  
All GAPs are composed of numerous domains including a finger-like domain 
(Wittinghofer et al., 1997). The highly conserved finger-like domain is usually an 
arginine finger which interacts with the phosphate-binding loop (P-loop) of Ras. This 
interaction increases the GTP hydrolysis more than 1000-fold by stabilising the 
transition state (Scheffzek et al., 1997). GAPs reduce in this way the number of 
RasGTP molecules available for interaction with the downstream effectors, leading to 
an attenuation or termination of downstream signalling. At least GAPs are able to 
control the rise and fall of RasGTP levels, but its still unknown if GAP activity is 
constitutive or subject to cellular fine-tuning and regulation.  
The sub-cellular localisation of Ras signalling complexes, protein-protein interactions, 
protein degradation and second messenger as well post-translational modifications 
makes the GTPase activity control highly complex and is intensely debated by (Bos 
et al., 2007) and (Grewal et al., 2011). The control and regulation mechanisms 
consider that RasGAPs are critical elements in growth factor signalling and bridge the 
link between activated receptor tyrosine kinases and the small GTPase Ras. 
p120GAP was the first characterised GAP protein with an N-terminal SH3 domain 
flanked by two SH2 domains (Figure 5) that directly recognise phosphorylated 
tyrosines on activated growth factor receptors and cytoplasmic proteins 
(Pamonsinlapatham et al., 2009). Further it is postulated that the PH domain 
mediates the interaction with Ras (Drugan et al., 2000). For the C2 domain it has 
been proposed that it mediates protein-protein interactions with Ca2+-dependent 
membrane-binding proteins. p120GAP is also known as a multi-interacting protein in 
downstream signalling due to its associations with Akt, Aurora or p190RhoGAP (a 
GAP protein for the Rho family of small GTPases) (Pamonsinlapatham et al., 2009).  
NF1 is a large tumour suppressor protein harbouring a central RasGAP region 
(Martin et al., 1990). Intriguingly, NF1 lacks other functional protein domains that 
could potentially serve as a link to cell surface receptor signalling, except of the 
phospholipid-binding Sec14-PH module juxtaposed to the RasGAP domain (Welti et 
al., 2007) (Figure 5). Studies reported that specific lipids like arachidonic acid and 
phosphatidic acid have strong inhibitory effects on NF1 catalytic activity but do not 
influence the Ras/NF1 interaction (Tsai et al., 1989, Bollag and McCormick, 1991, 
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Han et al., 1991). NF1 is known to interact with all four mammalian syndecans 
(Hsueh et al., 2001), transmembrane proteins, which enables recruiting NF1 to 
specialised domains of the plasma membrane to gain proximity to activated Ras or 
other functional proteins. However the significance of this observation remains 
unclear. Further it was shown that NF1 is phosphorylated at the C-terminal region by 
protein kinase A. Such a phosphorylation encourages the association with 14-3-3 
proteins and correlates with a decreased GAP activity (Izawa et al., 1996, Feng et al., 
2004). Interestingly, alternative splicing of the NF1 pre-mRNA influences the NF1 
mediated GTP hydrolysis intensity. Herein exon 23a is an alternative exon inside the 
GAP-related domain and exon 23a exclusion displays a 10 times higher GAP activity 
(Zhu et al., 2008, Barron and Lou, 2012, Hinman et al., 2014). Furthermore 
proteasomal degradation seems to be important in the regulation of NF1 abundance 
(Cichowski et al., 2003). But nothing is really known about NF1 function and 
regulatory mechanisms in Ras activation/deactivation. Although biochemical studies 
have failed to integrate NF1 in specific signalling pathways or its precise role in 
controlling Ras signalling pathways, NF1 remains a noteworthy candidate. In addition 
to its role of resolving Ras signalling, studies in Drosophila melanogaster have shown 
that NF1 affects adenylyl cyclase activity and consequently cAMP levels (Guo et al., 
2000, Walker et al., 2013), although the underlying molecular mechanism remains 
elusive. 
In mammalian cells the GAP1 family comprises four proteins: GAP1m, GAP1IP4BP, 
CAPRI (Ca2+-promoted Ras inactivator) and RASAL (Ras-GTPase activating-like 
protein) (Yarwood et al., 2006). They all share conserved structural modules, 
including tandem C2 (calcium-dependent phospholipid-binding) domains, the 
catalytic RasGAP domain, and a PH domain next to a Bruton tyrosine kinase (BTK) 
motif (Figure 5). Thus they are controlled by Ca2+ oscillations and inositol phosphate 
lipid levels. For example plasma membrane localisation and concomitant GAP 
activity of RASAL and CAPRI correlate with the Ca2+ concentration in the cell 
(Lockyer et al., 2001, Walker et al., 2004). In contrast, GAP1IP4BP is constitutively 
membrane bound though requires binding of a Phospholipase C to its PH domain for 
GAP activity  (Cullen and Lockyer, 2002).  
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SynGAP is only expressed in neurons and has been implicated in the inactivation of 
Ras activity at excitatory synapses (Kim et al., 1998). SynGAP catalytic activity is 
regulated through phosphorylation via the cyclin-dependent kinase 5 and the 
Ca2+/calmodulin-dependent protein kinase II (Oh et al., 2004, Walkup et al., 2015). 
Remarkably GAPVD1 (GTPase activating protein and VPS9 domains 1) can act via 
the RasGAP domain as a GAP and via the VPS9 domain as a GEF for Rab31 (Lodhi 
et al., 2007).  
In addition GAPs are considered to have dual functions in the cell depending on the 
domain variety. On the one hand the down regulation of the Ras/MAPK pathway after 
growth factor stimulation (signal terminator) and on the other the transduction of 
downstream signals (signal transmitter) to regulate cellular processes involved in 
apoptosis, proliferation and cell migration (McCormick, 1989, Hall, 1990b, 
Pamonsinlapatham et al., 2009). 
 
Figure 5: Domain architecture of RasGAPs.  
The six RasGAP families with the functional and catalytically domains are shown. Domain 
nomenclature according to SMART database (http://smart.embl-heidelberg.de/): BTK, Bruton’s 
tyrosine kinase Cys-rich motif; C2, protein kinase C conserved region 2; CSRD, cysteine and serine 
rich domain; PH, Pleckstrin homology; RasGAP, catalytic domain of GTPase activating protein for 
Ras; SEC14, lipid-binding domain; SH2, Src homology 2 domain; SH3, Src homology 3 domain; 
VPS9, domain present in VPS9 protein. Figure based on (Hennig et al., 2015). 
 
GAPs in malignancies 
Based on the Ras-inactivating nature of GAP proteins, mutations and aberrant 
regulation leading to loss of GAP function have putative oncogenic potential. 
Fibroblasts derived from P120GAP deficient mice showed an increased and 
prolonged activation of Ras MAPK pathway, but they showed no abnormal or 
excessive cell proliferation, arguing that p120GAP is not required for mitogenic 
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signalling. This might be due to compensating effects by alternative GAPs, or due to 
reorganisation of signalling networks (Henkemeyer et al., 1995, van der Geer et al., 
1997). Furthermore, the P120GAP−/ − null mice have vascular defects and display 
neuronal apoptosis (Henkemeyer et al., 1995). Therefore loss of function of 
P120GAP seems to be involved in angiogenesis and the development of capillary 
and arteriovenous malformations (Tidyman and Rauen, 2009) (Figure 7). 
Contemporary reports have considered DAB2IP as a tumour suppressor in prostate 
cancer with growth inhibitory and pro-apoptotic activities via Ras-dependent  
and -independent pathways, which supports its role in maintaining cell homeostasis 
(Figure 7) (Chen et al., 2002, Chen et al., 2003, Xie et al., 2009). DAB2IP expression 
levels were also found to be lower in samples of patients with hepatocellular 
carcinoma and hepatocellular carcinoma cell lines (Calvisi et al., 2011, Zhang et al., 
2012). In addition, various studies have shown that the DAB2IP gene is inactivated in 
several cancers due to aberrant promoter hypermethylation, e.g. in gastrointestinal 
tumour (Dote et al., 2005), lung (Yano et al., 2005), prostate (Chen et al., 2003) and 
breast cancers (Dote et al., 2004).  
For NF1 several independent groups have reported that primary cells (fibroblasts, 
Schwann cells and neurons) derived from NF1 mutant embryos revealed widespread 
developmental abnormalities (Jacks et al., 1994). The hallmarks of neurofibromatosis 
type 1 include development of benign nerve and skin tumours and an increased risk 
of developing other malignancies (Thiel et al., 1995, Upadhyaya et al., 2008, 
Gulhane and Kotwal, 2015, Nishida et al., 2015). Consistent with the RasGAP 
function, loss of NF1 results in elevated levels of RasGTP and activation of its 
corresponding downstream effectors leading to aberrant proliferation and 
differentiation in multiple cell types (Basu et al., 1992, DeClue et al., 1992, Bollag et 
al., 1996, Guha et al., 1996, Wu et al., 2006).  
Studies targeting NF1 heterozygously indicated that these mice do not have 
neurofibromatosis (Brannan et al., 1994, Vogel et al., 1999) whereas chimeric 
animals harbouring, heterozygous and NF1 null cells developed neurofibromatosis 
implicating NF1 wild type allele loss is rate-limiting in tumourigenesis (Cichowski et 
al., 1999, McClatchey and Cichowski, 2001). Likewise, several other GAP species 
are implicated in human diseases, but are beyond the scope of this thesis.  
For further information Cichowski et al. have recently reviewed the role of RasGAPs 
in cancer (Maertens and Cichowski, 2014). 
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6.4 Ras signalling 
6.4.1 Activation of Ras by receptor tyrosine kinases 
Cell surface receptors are generally divided into 3 classes: 1) the ion channel-linked 
receptor 2) the enzyme-linked receptor and 3) G protein-coupled receptor.  
The intracellular domain of the enzyme-linked receptor has a catalytic function which 
catalysis receptor autophosphorylation and phosphorylation of substrates. The 
largest group of enzyme-linked receptors are tyrosine kinase receptors. Several 
types of receptor tyrosine kinases (RTKs) are known (Choura and Rebai, 2011). 
The EGFR (ErbB-1) was the first discovered member of the RTK class also named 
ErbB family (Lemmon and Schlessinger, 2010). Many ligands are able to activate 
EGFR such as the epidermal growth factor (EGF). EGF binding causes receptor 
dimerisation and leads to an activation of the EGFR (Heldin, 1995, Schlessinger, 
2002). EGFR activate a number of different intracellular signalling pathways for 
instance the Ras-MAPK (Jorissen et al., 2003), PI3K (phosphoinositide 3-kinase), 
Phospholipase C (PLC) (Chattopadhyay et al., 1999), and the Jak/STAT pathways 
(Quesnelle et al., 2007). In this work we focus on Ras signalling.  
EGFR exhibits an intrinsic protein-tyrosine kinase activity that transfers the  
γ-phosphate of bound ATP to the tyrosine (Y) residues of exogenous substrates and 
the C-terminal receptor domain. Phosphotyrosine binding domain (SH2)-containing 
proteins like Src, Shc and Grb2 (growth factor receptor-bound protein 2) bind the 
receptor and serve as an intracellular docking site for SH2 effector proteins 
(Normanno et al., 2006). In this way adaptor proteins are localised to  
tyrosine-phosphorylated sites and mediate further intracellular reactions.  
The strength and duration of intracellular signalling from the EGFR are controlled by 
receptor internalisation and degradation which can be triggered through receptor 
association with intracellular signalling molecules; e.g. c-Cbl, a tyrosine 
phosphorylation substrate accelerates desensitisation by increasing receptor  
poly-ubiquitination (Levkowitz et al., 1999, Marmor and Yarden, 2004, Ravid et al., 
2004). Furthermore protein tyrosine phosphatases are able to inhibit EGFR signalling 
(Ostman and Bohmer, 2001). This tight regulation ensures cell homeostasis and is 
frequently compromised in cancer cells (Ostman et al., 2006). 
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6.4.2 Ras downstream effector signalling 
Growth factor stimulated EGFR signalling induces a robust accumulation of  
GTP-loaded Ras which represents the active form of that small GTP-binding protein. 
The activation of Ras is mediated by the binding of Grb2 either directly at the 
activated EGFR (Batzer et al., 1994) or indirectly, by binding to EGFR-associated, 
tyrosine phosphorylated Shc (Sasaoka et al., 1994). The N-terminal SH3 domains of 
the adapter protein Grb2 bind Sos1/2 (Sos) (Lowenstein et al., 1992, Li et al., 1993, 
Rozakis-Adcock et al., 1993). Sos functions as a guanine nucleotide exchange factor 
(GEF) and initiate the conversion of inactive GDP-bound Ras to the active  
GTP-bound form (Overbeck et al., 1995) (Figure 6). Ras inactivation is mediated by 
GAPs (GTPase-activating proteins) which enhance the intrinsic GTPase activity of 
Ras proteins and thereby returning Ras to the inactive GDP-bound state (Bos et al., 
2007) (Figure 6).  
Ras is a central signal transduction molecule due to its ability to activate downstream 
signalling pathways like Raf/MEK/Erk, PI3K/Akt/mTOR, Rac, Ral and the Protein 
kinase C (PKC) pathway (Malumbres and Barbacid, 2003) (Figure 6). In addition Ras 
is able to stimulate p38 and JNK, two other mitogen-activated protein kinases beside 
Erk (Cano and Mahadevan, 1995). Most effectors contain a Ras binding domain 
(RBD) or a Ras association (RA) domain. Despite the high-affinity Ras-effector 
binding, their interaction is rather temporary. The GTP hydrolysis and subsequent 
inactivation of Ras signalling provokes the release of effector molecules and 
termination of further downstream signalling events (Marshall, 1996).  
The Raf/MAPK pathway is evolutionarily conserved and one of the most intensively 
studied signal transduction processes downstream of Ras (Perrimon, 1994, 
Sternberg and Han, 1998). The essential elements in this pathway belong to a family 
of protein-serine/threonine kinases called the MAP kinases. The first mammalian 
effector of Ras is the serine/threonine-specific protein kinase Raf (Dickson et al., 
1992, Warne et al., 1993). Immediately after Ras activation Raf binds RasGTP via its 
RBD. Further phosphorylation events lead to entire Raf kinase activation (Rajalingam 
et al., 2005). Raf phosphorylates MAPK1/2 (MEK1/2), which subsequently activates 
extracellular-signal-regulated kinase 1/2 (Erk1/2). MAPKs like Erk phosphorylate 
substrates with the consensus sequence Px(S/T)P. The activated Erk has many 
substrates in the cytosol and the nucleus, including signal transducers and 
transcriptional regulators respectively (Yang et al., 1998, Roskoski, 2012).  
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Well-known Erk substrates are Rsk, cPLA2, MNK1/2, c-Fos and Elk-1. The diversity 
in cellular responses due to Erk signalling suggests that many Erk substrates have 
not been identified yet (Kosako et al., 2009).  
The 90 kDa ribosomal S6 kinases (Rsk) are a family of widely expressed Ser/Thr 
kinases characterised by two non-identical, catalytic domains connected by a 
regulatory linker region and a carboxy-terminal docking site for Erk (Anjum and 
Blenis, 2008). These domains gain full activity upon sequential phosphorylation 
events (Thr573, Ser380, Ser363, Thr359 and Ser221) following MAPK docking 
(Dalby et al., 1998). In mammals, four Rsk genes have been identified (Rsk1, Rsk2, 
Rsk3 and Rsk4). With the exception of Rsk4, expression of the Rsk mRNAs has 
been shown to be ubiquitous in every human tissue (Zeniou et al., 2002). RxRxxS/T 
or RRxS/T are the target sequences in known Rsk substrates (Leighton et al., 1995). 
The Rsk consensus phosphorylation motif is shared by other basophilic protein 
kinases, such as Akt, suggesting a functional overlap. Activated Rsk enzymes are 
mainly described to act further downstream to regulate cell survival (Bonni et al., 
1999, Shimamura et al., 2000) and cell growth by simultaneously regulating 
substrates that are involved in gene transcription and mRNA translation (Carriere et 
al., 2008, Romeo et al., 2012).  
The phosphoinositide 3-kinases (PI3K) catalyses the phosphorylation of membrane 
associated lipids thereby converting phosphatidylinositol (4,5)-bisphosphate (PIP2) to 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 propagates through binding of 
phosphoinositide-dependent kinase 1 (PDK1) the activation of the protein kinase B 
(PKB/Akt) which phosphorylates and activates other proteins. Moreover PI3K 
signalling activates the small GTPase Rac which is involved in cytoskeleton 
reorganisation (Castellano and Downward, 2011).  
Further Ras effector proteins are not part of this thesis work and will not be further 
described. 
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Figure 6: Ras activates multiple downstream effector pathways 
Ras is activated by epidermal growth factor receptor signalling at the cellular membrane by the 
ubiquitous expressed guanine nucleotide exchange factor Sos. Thereby GAPs stimulate the hydrolysis 
of GTP on Ras, returning them to their inactive state. The major Ras effector pathways are shown. 
The best-studied pathway activated by Ras is the Raf/MEK/Erk signalling cascade which leads to cell 
proliferation. PI3K take part in cell survival and proliferation. In addition active Ras stimulates RacGTP 
and RalGTP formation through TIAM1 a RacGEF and RalGEF. Figure based on (Schubbert et al., 
2007). 
6.5 Ras signalling in tumourigenesis 
Proto-Oncogenes like RAS are genes, which drive oncogenesis upon gain-of-function 
mutations. This leads to aberrant signalling and the dysregulation of the cellular 
functions such as cell proliferation and differentiation lead to cancer formation and 
tumour growth. Around 30% of all human cancers contain activating Ras mutations 
(Prior et al., 2012). Ras gain-of-function mutations occur frequently as point 
mutations in codon 12, 13 (P-loop) or 61 (Switch II) leading to amino-acid 
substitutions (Bos, 1989) (Figure 2). Interestingly these three major mutations are 
located in the nucleotide binding area. The mutations reduce the intrinsic GTPase 
activity of Ras and trigger a resistance towards the catalytic GAP activity (Trahey and 
McCormick, 1987, Zhang et al., 1990, Scheffzek et al., 1997). The subsequent 
attenuated activation of Ras and its effector pathways lead to cell transformation in 
culture and formation of human tumours.  
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Specific Ras genes are mutated in different malignancies (Bos, 1989) (Figure 7).  
K-Ras is the most common mutational activated oncoprotein and prevalent in 
pancreatic (95% frequency) (Hirai et al., 1985, Almoguera et al., 1988) as well in 
combination with N-Ras mutations in myeloid malignancies (Schubbert et al., 2007). 
Whereas N-RAS and H-RAS mutations have been detected in melanoma (Balmain 
and Pragnell, 1983) and bladder cancer (Fernandez-Medarde and Santos, 2011a), 
besides mutations in the H-RAS gene cause the Costello syndrome (Aoki et al., 
2005) (Figure 7).  
In addition to mutations of RAS there are several other classes of mutations that 
affect components of the Ras signalling for example the 1) growth-factor-receptor 
activation, 2) GAP deletion, or 3) overexpression of positive and negative regulators 
like Sos and Spred1 and 4) mutation or amplification of Ras effectors. All of these 
dysregulations were shown to cause several developmental disorders and/or cancer 
(Fernandez-Medarde and Santos, 2011a) (Figure 7). The genetic syndromes 
including Noonan-, Costello-, cardio-facio-cutaneous-, Legius syndrome and 
Neurofibromatosis type 1 are called RASopathies and show overlapping phenotypic 
features and symptoms that include facial abnormalities, heart defects, impaired 
growth and development (Simsek-Kiper et al., 2013).  
Many efforts have been made to develop cancer therapeutic agents targeting Ras or 
components of the Ras signalling pathway to treat various diseases, including 
cancer. For instance Farnesyltransferase inhibitors to block Ras membrane 
localisation, antisense oligonucleotides against Ras and Raf, kinase inhibitors 
targeting Ras effector pathways as well as small molecule tyrosine kinase inhibitors 
and monoclonal antibodies raised against the EGFR upstream of Ras (Downward, 
2003, Saxena et al., 2008). Taken together EGFR and the Ras/MAPK signalling 
cascade are important drivers of oncogenesis and in turn attractive targets for 
anticancer therapies. However, no clinically relevant direct Ras modulator has been 
yielded in the past and Ras proteins have been finally considered as “undruggable” 
(Cox et al., 2014). New directions in targeting of Ras pathways are excellently 
discussed elsewhere (Singh et al., 2015). 
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Figure 7: Overview of the main developmental disorders and tumours associated with aberrant 
Ras signalling.  
Gene mutations in the Ras/MAPK cascade and overexpressed EGFR causes diverse human cancers 
and developmental syndromes, the so called RASopathies. Here we display only a selection of all 
malignancies which are caused by aberrant Ras/MAPK signalling. Figure based on (Bentires-Alj et al., 
2006). 
6.6 Ras feedback mechanism and negative regulator in Ras signalling 
Early studies in the 90s proposed that the duration of the Ras/Erk signalling plays a 
critical role in cell fate decision (Traverse et al., 1992, Marshall, 1995a, von 
Kriegsheim et al., 2009). Nowadays it is still a matter of debate how the activation of 
the same canonical signalling cascades dictates distinct biological outcomes. Chris 
Marshall and co-workers delivered the first evidences in PC12 cells. They suggest 
that the duration and magnitude of Erk activation is critical for cell signalling 
decisions. NGF (nerve growth factor) and PDGF stimulated cells underwent cell 
differentiation in correlation with a prolonged Erk signal (Heasley and Johnson, 1992, 
Traverse et al., 1992). In contrast, EGF induced short-term Erk activity (Traverse et 
al., 1994), which led to cell proliferation (Nguyen et al., 1993, Marshall, 1995b). Later 
it was shown that EGF stimulation initiates a negative feedback loop, whereas NGF 
stimulation induces further signal amplification due to a positive feedback on the 
MAPK cascade (Brightman and Fell, 2000, Santos et al., 2007). One mechanism of 
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how cells sense the Erk signal duration is the accumulation of immediate early gene 
products in response to Erk activity (Murphy et al., 2002, Amit et al., 2007). 
A similar dynamic manner shows the Ras activity duration. Here the transient Ras 
activation induces proliferation or differentiation whereas a long term or sustained 
Ras activation induced by overexpression or constitutive active Ras in primary cells 
can induce senescence or growth arrest (Ridley et al., 1988, Serrano et al., 1997, 
Narita and Lowe, 2005). However, oncogene-induced senescence combined with 
other genetic lesions of a tumour suppressor protein like p53 or p16 promotes tumour 
progression (Serrano et al., 1997, Ferbeyre et al., 2002). This seems to be a major 
hurdle for cancer cells to achieve full transformation. At least for normal cell 
proliferation a transient Ras activation is necessary. Nevertheless how cells ensure a 
timely controlled, transient activation of Ras during mitogenic signalling is not yet 
clear. To terminate the Ras signal at the right time seems to be important for the 
cellular response. Whereas the Ras activation is triggered by enhanced exchange of 
guanine nucleotides on Ras, the mechanism responsible for the desensitisation of 
Ras (Ras deactivation) has remained obscure. The regulation of the active Ras is 
likely to occur at different levels, via inhibition or interruption of the upstream signals 
or negative regulation via a feedback loop starting downstream of Ras, here the 
signal induces or activates its own negative regulators.  
Previous studies demonstrated that insulin and several other agents (platelet-derived 
growth factor, serum, and phorbol ester) elicit a growth factor dependent 
phosphorylation of Sos and ensue disassociation of the Grb2-Sos complex (Waters 
et al., 1995a, Waters et al., 1995b, Dong et al., 1996). For the reason that Sos 
phosphorylation was correlated with the desensitisation phase of Ras inactivation 
they concluded that Grb2-Sos complex dissociation interrupt the ability of Sos to 
catalyse nucleotide exchange on Ras and thereby terminate the RasGTP formation. 
Finally, it has been postulated that Sos phosphorylation and following destabilisation 
of Sos-Grb2 complex occur by a MEK-dependent pathway (Figure 8A).  
Recently, a second phospho-dependent Ras-MAPK feedback loop targeting Sos has 
been suggested. Here Rsk phosphorylates Sos and in turn generates a  
14-3-3-docking site (Figure 8B). 14-3-3 binding has be suggested to reduce Sos 
catalytic activity or prevent its interaction with Ras or diminish the capacity for Sos to 
bind to the plasma membrane and thereby attenuate Ras-MAPK signalling (Saha et 
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al., 2012). These data demonstrated a further molecular feedback mechanism from 
MAPK pathway to the exchange factor Sos.  
Furthermore the Erk pathway is able to induce the transcriptional upregulation of 
sprouty proteins (Ozaki et al., 2001, Murphy et al., 2002, O'Donnell et al., 2012). 
Sprouty proteins are known to bind Grb2 and are thought to impede the activation of 
Sos proteins thereby decreasing Ras activation (Casci et al., 1999, Reich et al., 
1999, Hanafusa et al., 2002) (Figure 8C). Additionally, Cbl proteins are able to 
downregulate RTKs through Grb2 mediated Cbl-RTK binding and subsequent multi-
ubiquitylation (Thien and Langdon, 2001, Huang and Sorkin, 2005, Lee et al., 2014). 
In this context endocytosis of RTKs has been considered to regulate MAPKs as well 
(Dikic, 2003, Wiley, 2003, Marmor and Yarden, 2004).   
Further negative regulators of MAPK signalling are the Spred proteins. Spred1 
inhibits the activation of MAP kinase by suppressing phosphorylation and activation 
of Raf (Wakioka et al., 2001) (Figure 8D).  
The Ras activation process depends on its membrane localisation and subsequent 
spatial vicinity to membrane receptors (Zhou and Hancock, 2015). At least the 
mechanisms that drive Ras in microdomains are unknown but could be another 
possible regulatory tool in the context of Ras activity regulation (Rotblat et al., 2010) 
(Figure 8E). 
RasGAPs like NF1 are known as negative regulators of Ras due to their intrinsic 
catalytical GTPase activating domain (Figure 8F). Despite indisputable advances in 
our understanding of the functional characteristics of GAP enzymes and based on 
the huge awareness of the tumour suppressive roles of DAB2IP and NF1, there is 
little knowledge on their molecular mechanisms and cellular regulation. During the 
last years RasGAPs have been in the shadow of GEF biology as the important driver 
and regulator of Ras activity. An important goal is to determine the extent of GAP 
activity contributing to the deactivation of Ras signalling upon growth factor 
stimulation. It has not been shown how GAP activity shapes the amplitudes and 
duration of Ras signalling. Furthermore, the signalling events downstream of 
activated growth factor receptors which induce and fine-tune RasGAP engagement 
as well as GAP activity have not been resolved yet. Taken together, we still lack solid 
evidences, which convincingly document the modulation of growth factor signalling by 
GAPs.  
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In this context open and interesting questions are: Are there Ras GAPs acting 
downstream of an activated growth factor receptors? And which signalling events 
drive the interaction of GAPs and Ras? In this study it was our ambitions to answer 
these questions.  
 
Figure 8: Possible Ras feedback mechanisms.  
The Ras pathway is highly regulated and exhibits a negative feedback signalling network. This figure 
includes many, but not all, negative regulators and proposed feedback loops in growth factor signalling 
(shown in red). A+B) Erk and Rsk are suggested kinases to initiate the negative feedback loop 
downstream of Ras via Sos phosphorylation. C) Sprouty proteins are immediate early gene products 
of Erk and proposed to decrease the Sos activity through Grb2 binding. D) Spred1 diminishes the 
MAPK signalling by directly disruption of the Ras-Raf binding. E) The reorganisation of Ras molecules 
on the plasma membrane is another thinkable Ras downregulating mechanism. F) GAP proteins 
function as a negative regulator by direct interaction with Ras molecules for GTP hydrolysis. Whereas 
the GTP hydrolysis on Ras is described in detail, the mechanisms how GAPs become activated after 
growth factor stimulation are not known. 
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7 Aim of the work 
The duration of Ras activity determine cell fate decisions. Growth factor-induced Ras 
activation must be transient to drive cells into the cell cycle and to promote a proper 
proliferative response. Mutations in Ras lead to constitutive Ras activation and 
promote senescence. In combination with another oncogene or inactivation of a 
tumour suppressor, oncogenic Ras triggers cell transformation. Hence, many studies 
focused on investigating the role of mutated, oncogenic Ras in cell signalling and 
tumour development. In contrast, the mechanodynamics of transient Ras activation in 
growth factor signalling in normal cell function is largely understudied. The current 
understanding is that Ras activation in quiescent cells arises through the activation of 
Sos, which consequently results in the stimulation of nucleotide exchange on Ras. 
The principle behind the decline of RasGTP levels, further referred as Ras 
deactivation, is poorly understood. Current models argue for a negative feedback on 
Sos, based on the observation that Sos becomes phosphorylated following the 
activation of Ras/MAPK pathway. However, this assumption was never tested 
experimentally. In theory, the restoration of basal RasGTP level could be mediated 
by diverse mechanisms: 1. Suppression of GEF activity, herein GAPs play a rather 
passive role. 2. Activation of GAP(s). 3. A combination of GEF inhibition and GAP 
activation could synergise to switch off Ras. The current thesis work aims to address 
following questions: 
a) Which mechanisms terminate growth factor induced Ras activation? 
b) How do feedback loops contribute to Ras deactivation? Do these 
feedbacks impact Sos activity, as originally proposed, or do they engage 
GAPs? 
c) If Ras deactivation is driven by a GAP system, what is the identity of the 
relevant GAP? 
d) Are GAPs constitutively active enzymes or targets of cellular signalling? 
What are the mechanisms leading to GAP activation?  
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8 Materials and Methods 
8.1 Material 
8.1.1 Reagents 
 
Table 1: List of reagents 
Reagent Company 
Acetic acid Carl Roth GmbH & Co. KG 
Acrylamide/Bis-acrylamide 30% (37.5:1) Carl Roth GmbH & Co. KG 
[alpha-32P]GTP Hartmann Analytic 
Amersham Hyperfilm MP GE Healthcare 
Ammonium formate Carl Roth GmbH & Co. KG 
Ammonium persulphate (APS)  SERVA Electrophoresis GmbH  
Bovine serum albumin (BSA) PAA 
Bromophenol blue Carl Roth GmbH & Co. KG 
Calcium chloride (CaCl2) Sigma-Aldrich  
Coomassie Brillant Blue R250 Sigma-Aldrich 
Deoxycholic acid sodium salt Carl Roth GmbH & Co. KG 
Diethylpyrocarbonat (DEPC) Sigma-Aldrich 
Dimethyl sulfoxide (DMSO)  Merck, Darmstadt 
Dithiothreitol (DTT) AppliChem GmbH 
DMEM Sigma-Aldrich 
Epidermal growth factor Life Technologies 
Ethylene glycol tetraacetic acid (EGTA) AppliChem GmbH 
Ethylene diamine tetraacetic acid (EDTA) Carl Roth GmbH & Co. KG 
Fetal calf serum (FCS) Biowest 
GammaBind–Sepharose  Amersham Biosciences 
GeneJuice® Transfection Reagent Novagen 
Glutathione Sigma-Aldrich 
Glutathione–Sepharose JenaBioscience GmbH 
Glycine PUFFERAN® Carl Roth GmbH & Co. KG 
GppNHp JenaBioscience GmbH 
GST–Raf-1-RBD Lab-intern 
Guanosine diphosphate (GDP)  Sigma-Aldrich 
Guanosine triphosphate (GTP)  Sigma-Aldrich 
HEPES AppliChem GmbH 
Hydrochloric acid Carl Roth GmbH & Co. KG 
Isopropyl β-D-1-thiogalactopyranoside (IPTG)  Calbiochem 
Leupeptin-hemisulphate AppliChem GmbH 
Lysozym Sigma-Aldrich 
Magnesium chloride (MgCl2) AppliChem GmbH 
2-Mercaptoethanol Carl Roth GmbH & Co. KG 
Microycystin-LR Enzo Life Sciences GmbH 
N,N,N´,N´-Tetramethylendiamine (TEMED) Carl Roth GmbH & Co. KG 
Nonylphenylpolyethylenglycol (NP)-40 Merck KGaA  
PageRuler™ Plus Prestained Protein Ladder Thermo Fisher Scientific Inc. 
PageRuler™ Prestained Protein Ladder Thermo Fisher Scientific Inc. 
Pefabloc SC® (AEBSF hydrochloride) AppliChem GmbH 
Pepstatin A AppliChem GmbH 
PMSF (Phenylmethylsulfonylfluoride) Sigma-Aldrich 
Polyethylenimine (PEI) branched Sigma-Aldrich 
Polyvinylidendifluoride (PVDF) membrane GE Healthcare 
Potassium acetate Carl Roth GmbH & Co. KG 
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Potassium chloride (KCl) Carl Roth GmbH & Co. KG 
Potassium L-glutamate Sigma-Aldrich 
Saint Red Synvolux Therapeutics 
Sepharose CL-4B Sigma-Aldrich 
Sodium chloride (NaCl) Carl Roth GmbH & Co. KG 
Sodium Deoxycholate Sigma-Aldrich 
Sodium dodecyl sulfate (SDS) AppliChem GmbH 
Sodium orthovanadate Sigma-Aldrich 
Sodium-β-glycerophosphate SERVA Electrophoresis GmbH 
Streptolysin O (SLO) Aalto Bio Reagents Ltd. 
TLC PEI Cellulose F  Merck 
Tris ultrapure AppliChem GmbH 
Triton X-100 Carl Roth GmbH & Co. KG 
Trypsin-EDTA      Life Technologies 
Tween®20  Serva 
Western Lightning ECL, Enhanced 
Chemiluminescent Substrate 
PerkinElmer 
Whatman filter paper Bio-Rad Laboratories Inc. 
 
8.1.2 Buffers and solutions 
Table 2: Buffers for Sodium Dodecyl Sulfate - Polyacrylamide Gel Electrophoresis 
10x SDS running buffer 2x SDS sample buffer 5x SDS sample buffer 
250 mM Tris 20% Glycerol 33% Glycerol 
2 M Glycine 4% SDS 5% SDS 
35 mM SDS 10% 2-Mercaptoethanol 25% 2-Mercaptoethanol 
 0.02% Bromophenol blue 0.02% Bromophenol blue 
 124 mM Tris pH 6.8 85 mM Tris pH 6.8 
Coomassie staining 
solution 
Stacking gel buffer Separating gel buffer 
0.5% Coomassie Brilliant 
Blue R250 in absolute 
ethanol mix 1:1 with 20% 
acetic acid 
0.5 M Tris pH 6.8 
 
2 M Tris pH 8.8 
 
 
Table 3: Buffers for Western blotting and immunodetection 
Transfer buffer pH 10 Stripping buffer pH 6.7 10x TBS-Tween pH 7.6 
48 mM Tris 100 mM 2-Mercaptoethanol 100 mM Tris 
39 mM Glycine 62.5 mM Tris 1 M NaCl 
0.037% SDS 2% SDS 1% Tween 20 
15% Methanol   
Blocking solution ECL  
1x TBS-Tween 50% Oxidizing Reagent Plus  
1% BSA 50% Enhanced Luminol 
Reagent Plus 
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Table 4: Buffer for Ras activity assay 
Lysis buffer 
50 mM Tris pH 7.5 Protease inhibitors 
140 mM NaCl 42 mM Pefabloc 
5 mM MgCl2 2 μM Leupeptin 
1 mM EGTA 100 μM PMSF 
1% NP-40 1.5 μM Pepstatin A 
Add freshly Phosphatase inhibitors 
100 μM GDP 100 μM Sodium vanadate 
2 mM DTT 1 µM β-Glycerophosphate 
25 µg/ml purified GST-Raf-1-RBD 3.4 nM Microcystin 
 
Table 5: Buffers for Nucleotide exchange assay 
Lysis buffer Permeabilisation solution Washing solution 
50 mM Hepes pH 7.5 50 mM Hepes pH 7.5 50 mM Hepes pH 7.5 
100 mM NaCl 23 mM NaCl 500 mM NaCl 
10 mM MgCl2  3 mM MgCl2 5 mM MgCl2 
1% NP-40 100 nM CaCl2 0.1% TX-100 
 1 mM EGTA 0.005% SDS 
Add freshly Add freshly  
100 µM GDP  107 mM K-glutamate  
100 µM GTP  1 mM ATP  
2.5 µg/ml Y13-259  2 mM DTT  
Protease inhibitors 
9 MBq [α-32P]GTP 
15 IU/ml SLO 
 
Phosphatase inhibitors    
Elution solution TLC mobile Phase   
5 mM DTT    
5 mM EDTA 
0.2% SDS 
0.5 mM GDP 
0.5 mM GTP 
1.24 M Ammonium formiate 
3.7% HCl 
 
Table 6: Buffer for Nanocluster assay 
KOAc buffer Staining solution Fixative solution 
25 mM Hepes pH 7.4 0.6% Uranyl acetate 1x KOAc buffer 
115 mM K-acetate 1.8% Methyl cellulose 0.1% glutaraldehyde  
2.5 mM MgCl2  4% paraformaldehyde 
Blocking solution   
1x KOAc buffer   
0.2% Fish skin gelatine   
0.2% BSA   
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8.1.3 Antibodies 
Table 7: List of antibodies for western blot analyses 
Primary Antibodies 
Name Source Company Dilution Cat. No. 
Akt rabbit Cell Signaling 
Technology® 
1:2000 9272 
DAB2IP rabbit Abcam 1:1000 ab87811 
Ras-GAP (clone 13/RAS-
GAP) 
mouse BD Transduction 
Laboratories™ 
1:1000 610040 
EGF receptor  rabbit Cell Signaling 
Technology® 
1:2000 4267 
FLAG® M2 mouse Sigma Aldrich® 1:1000 F3165 
GFP Gold-conjugated sheep Prepared and kindly 
provided by Alison 
Beckett 
7-10 
µg/ml 
 
GSK-3β (27C10) rabbit Cell Signaling 
Technology® 
1:1000 9315 
K-Ras F234 
 
mouse Santa Cruz 
Biotechnology® 
1:1000 sc-30 
Neurofibromin (D) rabbit Santa Cruz 
Biotechnology® 
1:1000 sc-67 
N-Ras F155 mouse Santa Cruz 
Biotechnology® 
1:500 sc-31 
p44/42 MAPK (ERK1/2) ) 
(137F5)   
rabbit Cell Signaling 
Technology® 
1:1000 4695 
P-Akt Substrate 
(RXRXXS/T)(110B7)   
rabbit Cell Signaling 
Technology® 
1:1000 9614 
pan-Ras C-4 mouse Santa Cruz 
Biotechnology® 
1:500 sc-166691 
p-EGF Receptor (Y1068) rabbit Cell Signaling 
Technology® 
1:1000 2236 
p-ERK1/2 (Y204)  mouse Santa Cruz 
Biotechnology® 
1:1000 sc-101761 
Phospho-(Ser/Thr) Akt 
Substrate 
rabbit Cell Signaling 
Technology® 
1:1000 9611 
Phospho-GSK-3β (Ser9) 
(D85E12) XP® 
rabbit Cell Signaling 
Technology® 
1:2000 5558 
Phospho-p90RSK 
(Ser380) 
rabbit Cell Signaling 
Technology® 
1:1000 9341 
pS473-Akt rabbit Cell Signaling 
Technology® 
1:2000 4060 
RSK1/RSK2/RSK3 
(32D7) 
rabbit Cell Signaling 
Technology® 
1:1000 9355 
SOS1 (clone 25/SOS1) mouse BD Transduction 
Laboratories™ 
1:1000 610095 
Spred 2 rabbit Sigma Aldrich® 1:1000 S7320 
Y13-259 used for IP anti-
Ras 
rat Lab-intern 2.5 µg/ml  
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Secondary Antibodies 
Name Source Provider Dilution 
HRP-labelled anti-mouse goat polyclonal KPL® 1:10000 
HRP-labelled anti-rabbit goat polyclonal KPL® 1:10000 
 
8.1.4 Inhibitors 
Table 8: List of inhibitors 
Inhibitor Name Provider Final 
concentration 
Cat. No. 
AKT inhibitor Wortmannin Sigma Aldrich® 100 nM W1628 
EGFR inhibitor AG1478 Merck Millipore 250 nM 658552 
ERK inhibitor FR108204 Sigma Aldrich® 50 µM SML0320 
MEK inhibitor U0126 Enzo Life Sciences 10 µM BML-EI282 
RSK inhibitor BI-D1870 Enzo Life Sciences 10 µM BML-EI407 
p38 inhibitor SB202190 Sigma Aldrich® 10 µM S7067 
 
8.1.5 siRNA 
All siRNAs containing a mixture of four SMARTselection designed siRNAs targeting 
one gene, purchased from Dharmacon and dissolved in DEPC-water with a 
concentration of 250 ng/µl. siRNA concentration and integrity were analysed 
spectrophotometrically with a NanoPhotometer (Thermo Fisher Scientific Inc.).  
Table 9: List of siRNAs 
Target gene Cat. No. 
Human DAB2IP L-008249-01-0005 
Human NF1 L-003916-00-0005 
Human RASA1 (5921)  L-005276-00-0005 
Human RPS6KA1 (Rsk1) L-003025-00-0005 
Human RPS6KA3 (Rsk2) L-003026-00-0005 
8.1.6 Real-time qPCR primer 
Table 10: List of primers 
cDNA Orientation Sequence 5´ to 3´ 
Rps6ka1 
(RSK1) 
forward ccggctctcaaaagaggtg 
reverse agctcggccaggtaaaactt 
Rps6ka3 
(Rsk2) 
forward gcatgataagctgtttaaatgtcc 
reverse caaaatgtcatatactttgctagttgc 
Rps6ka2 
(RSK3) 
forward ttaagcgccatcccttctt 
reverse ggtttgaacggtggcttg 
Rps6ka6 
(Rsk4) 
forward ggtggtcatatggtgttcttatgt 
reverse ggtctcatttctgtctttaccttga 
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The primer sequences were adapted from Romeo et al. 2013 (Romeo et al., 2013). 
 
8.1.7 Plasmids 
Table 11: List of plasmids 
Name Vector Source 
DAB2IP pcDNA3.1 Kindly provided by Prof. Jer-Tsong 
Hsieh (University of Texas 
Southwestern, USA) 
FLAG-Spred2 pCMV2-FLAG(N) Kindly provided by Akihiko Yoshimura 
(Keio University School of Medicine, 
Japan) 
GFP-CAPRI pEGFP-C2 Kindly provided by Prof. Peter Cullen 
(University of Bristol, UK) GFP-GAP1IB4BP pEGFP-C1 
GFP-GAP1m 
GFP-RASAL 
GFP-NF1 pCDH-EF1a-EGFP-C2-
IRESPuro 
Kindly provided by Yan Cui (FLI, 
Jena, Germany) 
HA-p120GAP pcDNA3 Kindly provided by Christian Widmann 
(University Lausanne, Switzerland) 
 
8.1.8 Kits 
Table 12: List of Kits 
Name Company Cat. No. 
RNA isolation kit Macherey-Nagel 740955 
First Strand cDNA Synthesis Kit Thermo Scientific K1611 
QuantiTect SYBR Green PCR Master 
Mix (2X) 
Qiagen 204141 
 
8.2 Methods 
8.2.1 Cell line and stimulations 
Cervical cancer (HeLa) cells, Mouse embryonic fibroblasts (MEFs), Human 
Embryonic Kidney 293 T (HEK293T) cells (kindly provided by Yan Cui, FLI, Jena, 
Germany) and H-Ras-/-, N-Ras-/-, K-Raslox/lox MEFs (kindly provided by Mariano 
Barbacid, Madrid, Spain) were cultured at 37°C and 5% CO2 atmosphere in DMEM 
(Dulbecco’s modified Eagle’s medium) supplemented with 10% (v/v) FCS.  
EGF was added to a final concentration of 10 ng/ml. Inhibitors such as U0126, 
FR108204, BI-D1870, Wortmannin, SB202190 and AG1478 were pre-incubated for 
30 min before stimulation.   
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• U0126 is a highly selective non-ATP competitive inhibitor of both MEK1 and 
MEK2 (Favata et al., 1998). 
• FR180204 is an ATP competitive inhibitor that prevents the catalytic activity of 
ERK1/2 but not its threonine and tyrosine residue phosphorylation (Ohori et 
al., 2005).  
• BI-D1870 is a specific ATP competitive inhibitor of RSK isoforms (Sapkota et 
al., 2007). 
• Wortmannin is an allosteric, non-ATP competitive inhibitor of the PI3K 
pathway (Powis et al., 1994, Wymann et al., 1996). 
• AG1478 inhibits EGFR tyrosine kinase activity and receptor 
autophosphorylation by competitively binding to the ATP pocket of EGFR (Han 
et al., 1996). 
• SB202190 is a specific inhibitor of p38alpha and p38beta and binds within the 
ATP pocket of the active kinase (Davies et al., 2000). 
8.2.2 Transfection of cell lines 
Transient transfection 
Transient cell transfection with plasmid DNA was performed using branched 
Polyethylenimin (PEI). Briefly, cells were seeded in 6 well plates. HeLa cells can be 
efficiently transfected at 70-80% confluency. PEI reagent (10 µg/µl stock) was diluted 
1:20 in pre-warmed DMEM (25 µl to 500 µl), mixed and further diluted in DMEM 1:25 
(60 µl to 1500 µl). Further 1 µg DNA per well was dissolved in 250 µl plain DMEM 
and 250 µl of the PEI-DMEM solution were added, mixed thoroughly and allowed to 
complex by incubating 30 min at RT. The cell culture medium of the 6-well plate was 
replaced by 1 ml of plain DMEM. Then 500 µl of the PEI-DNA mix were added  
drop-wise per well. The cells were incubated and the medium was exchanged after  
3 hours to 2 ml DMEM supplemented with 10% FCS to overcome cellular toxicity by 
PEI-particles. After 24 hours cells were serum-starved overnight and prepared for 
western blotting. 
Acute knockdown via siRNA transfection 
For siRNA-mediated acute knockdowns ON-TARGETplus siRNA- SMARTpool™ 
from Dharmacon were used. Cells were seeded at a density of 30-40% confluency 
and transfected with 0.5 µg siRNA per well except of Rsk 2 where  
1 µg was used.  
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siRNA transfections were conducted with Saint-Red transfection reagent from 
Synvolux Therapeutics according to the manufacturer’s protocol. Cells were 
incubated for 48 h and starved overnight in the absence of serum.  
Stable knockdown via lentiviral transduction 
Neurofibromin was stably knocked down in HEK293T cells by Yan Cui (Leibniz 
Institute on Aging – Fritz Lipmann Institute (FLI), Jena) using the targeting sequence 
GCTGGCAGTTTCAAACGTAA. 
8.2.3 RNA isolation, cDNA synthesis and quantitative real-time PCR analysis 
Total RNA isolation and purification was performed using RNA isolation kit according 
to the manufacturer’s protocol. The RNA concentration and integrity was determined 
by spectrophotometric measurements at 260 nm and 280 nm.  
cDNA synthesis was performed using cDNA Synthesis Kit with 50 ng/μl of total RNA 
per sample and Oligo-dT-based priming. 
For quantitative real-time PCR (qRT-PCR) analysis, the QuantiTect SYBR Green 
PCR Master Mix (2x) was used. The master mixes contained 0.125 µM of each 
GAPDH or RpS6Ka1, RpS6Ka3, RpS6Ka2, RpS6Ka6 primer. The analysis was 
performed in triplicates using 1 µl of the cDNA preparation in a total reaction volume 
of 12 µl (Table 13). The PCR was performed in an Eppendorf MasterCycler 
RealPlex4 under the following conditions: 10 min of initial denaturation at 95°C 
followed by 45 cycles of [15s at 95°C, 30 s at 55°C and 40s at 72°C]. Melting curve 
analysis was subsequently performed. Relative transcript levels were determined by 
calculating 2ΔCt values, using GAPDH expression levels for normalisation.  
Table 13: qRT-PCR Reaction Mix 
Standard reaction Volume 
Template DNA 1 µl 
2x SYBR Green PCR Master Mix 6 µl 
Sense primer (10 µM) 0.37 µl 
Antisense primer (10 µM) 0.37 µl 
RNase-free water 4.26 µl 
total 12 µl 
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8.2.4 SDS-PAGE  
Electrophoretic separation of proteins was achieved by Sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) with a vertical slab electrophoresis 
system (Hofer scientific, California, #SE400) and 5 to 12.5% polyacrylamide gels. For 
analysis of proteins with a molecular weight in a range of 100-250 kDa the separating 
gel contained 5% acrylamide. Small proteins like Ras (21 kDa) as well proteins with a 
molecular weight up to 90 kDa were resolved in a 12.5% separating gel. SDS gels 
were run with SDS running buffer at a constant current of 25-30 mA per gel. 
Following SDS-PAGE, Coomassie staining was used for visualisation of the  
GST-Raf-1-RBD affinity probe. Then Western blotting and immunodetection were 
used for specific detection of proteins of interest. 
8.2.5 Western Blotting and immunodetection of immobilised proteins 
Western blotting by semidry transfer was applied for protein detection after 
separation via SDS-PAGE. Proteins were blotted with transfer buffer onto PVDF 
membranes. Generally, a 0.45 μm pore-sized PVDF membrane was used except for 
Ras-detection which was achieved by blotting onto a 0.20 µm pore sized membrane. 
Proteins were transferred under distinct conditions due to their different molecular 
weights which are listed in Table 14. 
After protein transfer, the membrane was incubated in blocking solution for 30 min at 
room temperature (RT). The blocked membranes were incubated in primary antibody 
solution at 4°C overnight. Next day, membranes were washed three times with  
1x TBS-Tween for 10 min and placed in the secondary antibody solution for 45 min at 
room temperature. Following three further washing steps with 1x TBS-Tween for  
10 min, membranes were covered with the HRP substrate (Western Lightning ECL) 
and the chemiluminescent signal was detected with the Fujifilm LAS-2000 
documentation system. After protein detection, stripping buffer was added for 30 min 
at 50°C and the membrane was washed again before adding 30 min blocking 
solution and another primary antibody. All incubation and washing steps were 
performed under shaking and all antibodies were diluted in blocking solution. 
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Table 14: Western Blot transfer conditions  
Protein Condition Molecular weight 
p38, Erk1/2, Gsk3ß, Akt 1 mA/cm2, 50 min 38–56 kDa 
N-; K-Ras 0.8 mA/cm2, 45 min 18-21 kDa 
NF1 1.5 mA/cm2, 75 min 250 kDa 
Rsk 1 mA/cm2, 60 min 90 kDa 
p120GAP, DAB2IP, EGFR, Sos1 1.5 mA/cm2, 60 min 120-170 kDa 
8.2.6 Expression and purification of the Raf-1-Ras binding domain 
The pGEX plasmid containing GST-Raf-1-Ras binding domain (RBD) was expressed 
in Escherichia coli BL21DE3pLysS. Expression was induced at an OD600 of 0.4 to 
0.6 with 0.1 mM IPTG for 2 h at 37°C. The cell pellet was then resuspended in Tris 
buffer (pH 7.5) containing 150 mM NaCl, 10 mM 2-Mercaptoethanol and freshly 
added protease inhibitors. The cell suspension was lysed by 3 freeze-thaw cycles 
and by adding of lysozyme, 1 mM EDTA and 1% Triton X-100. The lysate was 
clarified by centrifugation (30 min, 30 000 rpm and 4°C). GST-Raf-1-RBD proteins 
were purified directly from bacterial lysates via fast protein liquid chromatography 
(FPLC) by using a GSTrap™ FF (GE Healthcare) and by adding glutathione to the 
elution buffer. The purification method is based on the high affinity of GST for 
glutathione. Eluted proteins were further concentrated with Amicon® Ultra Centrifugal 
Filters (Merck Millipore) and free glutathione were removed via size exclusion by 
using pre-equilibrated gel filtration column with PBS. The protein-containing fractions 
were visualised by Coomassie staining following SDS-PAGE (Figure 9). The fractions 
containing the most RBD protein were collected afterwards. Finally, the protein 
concentration was determined by Bradford protein assay.  
 
Figure 9: Coomassie stained SDS-PAGE of fractions from RBD purification.  
Gel lanes were loaded with fractions collected after gel filtration. Predicted molecular weight of the 
RBD is 43 kDa. 
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8.2.7 Ras activity assay 
Activation of Ras was analysed by a RasGTP pulldown assay. For this purpose, 
active GTP-bound Ras was purified from cell extracts and analysed by Western 
Blotting. This approach was advantageous for measuring RasGTP levels at steady 
state conditions.  
Cells seeded in 6 well plates were deprived of serum overnight and treated as 
appropriate and lysed in 0.5 ml of ice-cold lysis solution supplemented with protease 
and phosphatase inhibitors, 100 μM GDP, 2 mM DTT and 25 μg/ml of soluble 
recombinant GST–Raf-1-RBD protein. The fusion protein was purified as explained 
above. GDP and GST–Raf-1-RBD were included in the lysis buffer to quench post-
lytic GTP-loading and GAP-dependent Ras-bound GTP hydrolysis. Cell material was 
scraped off and lysates were cleared by centrifugation (20 min,  
14 000 rpm, 4°C). GST-Raf-1-RBD/RasGTP complexes were collected on 
glutathione-sepharose (30 min at 4°C on a rotating wheel), washed once with 750 μl 
lysis buffer lacking GDP and GST–Raf-1-RBD and processed for Western Blotting. 
However, this Ras activity assay is unsuitable to directly probe the activity of the 
regulatory proteins (GEFs and GAPs) in the cell (Figure 10A). 
 
Figure 10: Comparison of the applied assays.  
A) RasGTP affinity purification was used to assess the steady state level of RasGTP in the cell lysate. 
B) The permeabilisation-based approach was performed to measure at pre-steady state the nucleotide 
exchange on Ras catalysed by GEFs. This figure is adapted from (Hennig et al., 2015). 
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8.2.8 Nucleotide exchange assay and Ras immunoprecipitation 
The Nucleotide exchange assay aimed to monitor, first, the rate of [α-32P]GTP uptake 
by Ras at pre-steady-state as readout for the activity of GEFs, and second, the  
[α-32P]GTP/[α-32P]GDP ratio on Ras, again at pre-steady-state (Figure 10B).  
Before cell permeabilisation serum-starved cells were seeded in 6-well plates and 
stimulated as appropriate. The plasma membrane permeabilisation were started by 
replacing the medium with 0.6 ml/well permeabilisation solution supplemented with  
9 MBq [α-32P]GTP and 15 unit/ml freshly thawed streptolysin O (SLO). The SLO, 
which is a bacterial toxin forms pores in the cell membranes and at same time 
perfuse the intact cells with [α-32P]GTP. For treated cells, this permeabilisation 
solution was supplemented with the relevant drug. At this point kinetics were started 
and due to the nucleotide exchange Ras binds rapidly [α-32P]GTP, which was 
immunoprecipitated and analysed. The higher the exchange rate, the more labelled 
Ras accumulated. The reactions were quenched by lysis with 1 ml of ice-cold lysis 
buffer supplemented with Y13-259 Ras-antibody per well for immunoprecipitation. 
Ras monoclonal antibody Y13-259 bound GTP and GDP-bound Ras proteins and 
prevented changes in the Ras loading state. Lysates were cleared by centrifugation 
(20 min, 14 000 rpm, 4°C) and supernatant was added to a final concentration of  
500 mM NaCl, 0.5% sodium deoxycholate and 0.05% SDS. Immunocomplexes were 
collected on GammaBind–Sepharose by 45 min incubation at 4°C under rotation. 
After six rounds of washing with 1 ml of ice-cold washing solution, 
immunoprecipitates were subjected to Cerenkov counting. Afterwards, Ras 
nucleotides were eluted from the samples and analysed by Thin Layer 
Chromatography (TLC).  
8.2.9 Thin layer chromatography 
Eluted Ras associated nucleotides were separated by thin layer chromatography 
(TLC) as reported by Rubio et al. (Rubio et al., 2003, Rubio et al., 2006). 30 µl of 
elution solution were added to the Ras-bound sepharose to elute the RasGDP/GTP 
from the samples. After 20 min incubation at 68°C in the thermoshaker, the samples 
were spun down and 16 µl of the supernatant were loaded stepwise (2 µl each step) 
on a PEI cellulose coated plate. The plate was placed for nucleotide separation in the 
mobile phase. For visualisation of the labelled nucleotides the TLC was exposed for  
4 weeks on film for autoradiography.  
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After sufficient exposure amounts of GTP and GDP bound to Ras-encoded protein 
were quantitated by densitometry using the Multi Gauge software. 
8.2.10 Mathematical modelling 
The ordinary differential equation (ODE) models were built in cooperation with 
Graham Ladds (University Cambridge) and Manuel A. Esparza-Franco (University of 
Warwick). In the model Ras cycles between GDP and GTP bound states with 
Michaelis-Menten kinetics, the balance of which depends on the GEF/GAP ratio. To 
simulate EGF stimulation, receptor recruits GEF to form receptor-GEF complex  
(R-GEF) increasing the rate of Ras-GTP formation. Downstream signalling from 
RasGTP enforces the feedback after a small time delay to account for the MAPK 
cascade. In the GEF-only model, feedback catalyses the separation of R-GEF 
complexes into free receptors and inactive GEF. In the GAP-only model, feedback 
catalyses the activation of GAP molecules. The parameters of each model will be 
available soon from Hennig, A. et al. in the journal Cell Communication and 
Signaling. 
8.2.11 Nanocluster assay 
The Nanocluster assay was performed in cooperation with Ian Prior and Alison 
Beckett (University Liverpool, UK) to determine the Ras molecule distribution at the 
inner leaflet of the plasma membrane by a combination of an electron microscopic 
(EM) approach coupled to sophisticated image analysis (Prior et al., 2003, Beckett 
and Prior, 2015). PM sheets were ripped off from adherent HeLa cells directly onto 
EM grids. For this purpose cells were grown on glass coverslips and transfected with 
GFP-H-Ras in 6-well plates with GeneJuice® Transfection Reagent following the 
manual instructions and incubated overnight in serum-free medium. Electron 
microscope grids were covered with pioloform and coated with poly-L-lysine. The 
coverslip with GFP-H-Ras transfected cells (70–80% confluent) was washed with  
0.1 M phosphate buffer (pH 7.35) then overlaid on the grids and pressure was 
applied using a silicon bung for 1 to 2 seconds. When the grid was removed large 
areas of the plasma membrane sticked to the grid. The grids were then washed by 
transferring them to a drop KOAc buffer on Parafilm M®. The plasma membrane 
sheet was fixed for 10 min with fixative solution followed by quenching free aldehyde 
groups by washing with 20 mM Glycine in for PBS three times 15 min each.  
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After blocking the non-specific antibody-binding sites with blocking solution for 10 min 
the plasma membrane sheets were immunolabeled with GFP antibody conjugated to 
gold particles for 30 min. The labelled grids were washed with blocking solution five 
changes for 5 min each and five times in water for 2 min each. All of the previous 
steps were carried out at RT. After washing, the ripped-off plasma membranes were 
incubated on ice for 10 min in a staining solution and picked up in 5-mm cooper wire 
loops and left to dry in the loops before analysing the H-Ras distribution by a 
transmission electron microscope (JEOL 1010). To analyse the complete gold 
patterns statistically, methods for point pattern analysis were used. Ripley’s  
K-function analysis (Ripley, 1977, 1979; Philimonenko et al., 2000) evaluates an 
exhaustive map of all interparticle distances over the study area and compares the 
observed distribution with that expected from complete spatial randomness.  
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9 Results 
9.1 EGF induces transient Ras activation  
It has been demonstrated that growth factors induce short-lived Ras activation in 
cells emerging from quiescence (Muroya et al., 1992, Qui and Green, 1992, Langlois 
et al., 1995b). Previous reports showed that this transient Ras activation is important 
for the induction of mitogenic programs (Marshall, 1995b, Crespo and Leon, 2000). 
However, the mechanisms terminating growth factor induced Ras activation is still 
unclear.  
In order to study Ras activity, an in vitro Ras activity assay was performed taking 
advantage of the Ras binding domain (RBD) to bind RasGTP. As a model system 
immortalised mouse embryonic fibroblasts (MEF cells) and a cervical cancer cell line 
(HeLa cells) were used due to easy manipulation and widely acceptance in this field 
of research. Robby Markwart (former Diploma student) showed that EGF stimulated 
HeLa cells display a well-defined transient Ras activation kinetic (Figure 11A) 
characterised by a strong increase in RasGTP levels within few minutes followed by 
a decline to basal levels after 5 min of EGF stimulation (Figure 11C). To examine 
whether this effect is mechanistically conserved, the Ras activity assay was repeated 
in MEF cells, and observed a similar transient pattern of RasGTP formation (Figure 
11B).  
The MAPK pathway is one of the downstream signalling cascades initiated by active 
Ras. The activity of this pathway can be measured by the phosphorylation of the 
downstream effector kinases for example Erk. The phospho-Erk level was probed for 
the indicated time points. In both cell lines, a sustained activation of Erk was 
observed exceeding the temporal profile of Ras activation (Figure 11).  
Previous studies have demonstrated that prolonged EGF stimulation results in EGFR 
internalisation or degradation and subsequent interruption of the upstream signalling 
of the Ras/MAPK pathway. To assess the EGFR activity different antibodies were 
used to detect various EGFR phosphorylation sites. In HeLa cells a continuous 
activation of the EGFR tyrosine autocrossphosphorylation sites Y1045 and Y1068 
(Figure 11) was detected. Thus, Ras activity decreases even in the presence of EGF 
receptor signalling. 
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Figure 11: EGF induces transient Ras activation.  
A) Transient Ras activation in HeLa cells. Serum-starved HeLa cells were challenged with 10 ng/ml 
EGF and Ras activation was determined via RasGTP activity assay. The two bands correspond to  
K-Ras and N-Ras (collectively referred to as Ras from here on). EGFR and Erk phosphorylation were 
determined using phosphosite-selective antibodies. RBD: Coomassie stain of Ras binding domain 
used for collecting RasGTP. B) MEF cells challenged with EGF were processed for Ras and Erk 
activity assays as in (A). C) A quantification of the RasGTP kinetics is shown. Figure A and C adapted 
from Robby Markwart. 
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9.2 Mathematical model describing the feedback stimulation of GAP activity 
The central dogma for Ras deactivation has been the downregulation of Sos, which is 
downstream of the growth factor receptor activation and drives the activation of Ras. 
In contrast, the role of RasGAPs downstream of active Ras is less characterised. To 
understand the contribution of GEFs as well of GAPs in Ras activation/deactivation a 
cooperation with Manuel A. Esparza-Franco (University of Warwick, UK) and Graham 
Ladds (University of Cambridge, UK) was started. They designed a mathematical 
model describing sequential growth factor-induced Sos activation, RasGTP formation 
and a RasGTP-driven feedback loop for Sos-inhibition (Figure 12A). This model is 
called GEF-only model for the reason that just one feedback loop to decrease GEF 
activity is included. On the basis of this model, they simulated Ras activation kinetic 
in the background of absent, low or high basal GAP activity (Figure 12B). The 
simulation demonstrated that a high basal GAP activity is needed to diminish the 
RasGTP level, as well if the system parallel invoke a feedback inhibition of Sos. In 
contrast, no or low GAP activity form a prolonged RasGTP level.  
To define the basal GAP activity in HeLa cells the basal GAP activity was 
manipulated via combined or single siRNA mediated knockdown of three major GAPs 
(p120GAP, DAB2IP and NF1) or GFP-NF1 / HA-RASA1 GAP overexpression in 
quiescent HeLa cells. In the Ras activity assay the basal RasGTP level did not 
change in GAP diminished cells, whereas the overexpression of NF1 triggered a 
slight decrease of the basal Ras level (Figure 12C). This experiment provided  
first-hand evidence for a low basal GAP activity in HeLa cells. 
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Figure 12: Mathematical model and basal GAP activity  
A) Minimal Ras model describing Ras deactivation as induced by RasGTP-dependent feedback 
inhibition of Sos (GEF-only model). B) Simulations of Ras activation/deactivation using the model from 
(A) in a background of absent, low or high basal GAP activity.  C) Basal RasGTP amount following 
manipulation of RasGAP levels via combined or single knockdown or GAP overexpression. 5 min EGF 
stimulation is shown as positive control after stimulation. The illustrations shown in A and B were 
provided by Manuel A. Esparza-Franco. 
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9.3 EGF mediates sequential engagement of Sos 
9.3.1 Sos is phosphorylated downstream of Ras 
Previous studies indicated the presence of negative feedback loops sparked 
downstream of Ras where the Ras effector kinases MEK, Erk and Rsk phosphorylate 
Sos after growth factor stimulation and thereby interfere with the ability of Sos to 
activate Ras (Waters et al., 1995b, Holt et al., 1996, Douville and Downward, 1997, 
Kim et al., 2006). As shown by Katharina Wolff (Master student), the phosphorylation 
of Sos (indicated by a electrophoretic mobility shift) follows EGF stimulation in HeLa 
cells. This phenomenon was abolished by treatment with a MEK or Erk specific 
inhibitor, whereas the pan-Rsk inhibitor treated cells showed Sos1 protein levels 
similar as untreated cells (Figure 13).  
 
Figure 13: EGF induces a mobility shift in Sos.  
HeLa cells were treated with inhibitors for MEK (U0126), Erk (FR108204) or Rsk (BI-D1870) prior to 
stimulation with 10 ng/ml EGF. Extracts were processed via western blotting using the indicated 
antibodies. The detection of pErk protein level served as MEK inhibitor control, whereas the pRsk 
signal was used to monitor the Erk-inhibition. p(Ser/Thr) Akt substrate protein levels validated the 
potency of the Rsk inhibitor. The arrow marks an unspecific doublet band. Figure was modified from 
Katharina Wolff. 
9.3.2 Sos activity does not decay with decline in RasGTP levels 
As a next step it was important to prove the assumption that Sos phosphorylation 
concomitantly downregulates Sos activity. The conventional Ras activity assay 
(Figure 10A) is limited by the assessment of the RasGTP level at steady state, the 
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nucleotide exchange assay was used for this purpose. This approach enabled to 
assay the nucleotide exchange at the pre- steady state. This is particularly relevant in 
view of the fact that EGF induced RasGTP accumulation could be caused either by 
an increase of nucleotide exchange on Ras or by the decrease of the GTP-hydrolysis 
activity of Ras. Therefore, the readout of the Ras activity assay is not suitable to 
distinguish between altered GEF and GAP action. The nucleotide exchange assay 
was technically achieved by streptolysin O (SLO) permeabilised cells and the 
measurement of direct binding of [α-32P]GTP to Ras over time. Afterwards the 
nucleotides bound to Ras were separated by thin layer chromatography (TLC), to 
monitor the RasGTP level under different conditions. The combined results of the 
applied permeabilisation assay and the TLC aimed to shed light on the actual status 
of GAP activity in cells. Up to know an assay to explore direct GAP activity is not 
feasible. Pretests validated that the radioactivity is specifically associated to Ras in 
[α-32P]GTP loaded HeLa cells. In the nucleotide exchange assay only the 
combination of the Ras-IP antibody together with SLO is able to raise the measured 
radioactivity. This effect was reversed by excess of cold GTP. Further, the specificity 
of the permeabilisation assay was shown before in other cell types (Rubio 2000). 
In order to investigate the effect of SLO permeabilisation on Ras activation, HeLa 
cells were permeabilised with SLO in the presence of EGF, followed by a Ras activity 
assay. This experiment revealed that Ras as well as its downstream targets such as 
Erk flow out of the cell over time, which affected the intensity of RasGTP levels but 
not the transient kinetic (Figure 14A). 
In the following experiments the nucleotide uptake at three different time points was 
examined to determine the role of GEFs in the feedback deactivation of Ras. At first, 
the nucleotide exchange of the unstimulated cells was measured, corresponding to 
the basal level of Ras nucleotide exchange activity. Next, 5 min post EGF stimulation, 
when RasGTP levels peaked (Figure 11C) it was measured. The EGF stimulation at 
this time point increased markedly the rate of nucleotide uptake by Ras and an equal 
accumulation of RasGTP in the same samples could be shown in the TLC (Figure 
14A). These data confirmed the commonly accepted view of GEFs being involved in 
EGF-induced Ras activation. In order to address the GEF activation at the time 
where the RasGTP level decreases the third measurement was set at 20 min after 
constant EGF exposure. Surprisingly, the data revealed a similar high nucleotide 
exchange rate on Ras at this late time point compared to 5 min post EGF stimulation 
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(Figure 14B and C). In contrast, the GTP level in the TLC dropped back (Figure 14B 
and C) as detected by the conventional Ras activity assay (Figure 11A). Furthermore, 
these findings were also verified in MEF cells (Figure 14D) underlining the 
importancy of this observation suggesting a general mechanism. Thus, the 
modulation of Sos activity is not the major driver of restoring basal RasGTP levels 
within this early window of growth factor stimulation. In line, we suggest that GAPs 
play an essential role in counteracting the high GEF activity and shut down of Ras 
activity. 
 
Figure 14: Please see legend on following page. 
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Figure 14: EGF induces transient RasGTP accumulation and prolonged up-regulation of 
nucleotide exchange.  
A) HeLa cells were permeabilised or not with SLO followed by EGF stimulation and subjected to a Ras 
activity assay. SLO was added simultaneously with EGF. B) Nucleotide exchange assay in 
permeabilised HeLa cells at 0, 5 and 20 min after EGF administration. Nucleotides associated to  
Ras-IPs were additionally eluted from Ras and separated via TLC (on the right).  
%GTP/(GDP +GTP) values were determined by densitometry and marked under the panel. Of note, 
initial values start off high and level off only at later time points. This pattern is due to the difference in 
time required for single Ras proteins versus the entire Ras population to achieve steady-state 
nucleotide turnover. C) Quantification of nucleotides bound to Ras-IPs 6 min after permeabilisation (as 
recorded in A). On the left, the amount of GDP + GTP bound to Ras was plotted as the fold increase 
of radioactivity bound to Ras in EGF-stimulated versus unstimulated cells. On the right, the amount of 
GTP expressed as percentage of GDP + GTP was plotted. Values are means ± S.E.M. for three 
independent experiments. D) Same experiment as in (B) performed in MEF cells. 
The previous data suggest that Ras deactivation is driven by increased GAP activity 
in a background of ceaseless high nucleotide exchange. To confirm this prediction a 
combination of the permeabilisation approach with the Ras activity assay was 
performed. For this purpose, the cells were loaded with GTP or with the  
non-hydrolysable GTP analogue GppNHp along with SLO permeabilisation and EGF 
stimulation. HeLa cells were lysed and the fraction of active Ras was assayed by the 
Ras activity assay. In GTP loaded cells the Ras activation is transient and returns to 
the basal state after 20 min EGF stimulation. In comparison, active Ras was 
accumulated after 5 and 20 min of EGF stimulation in GppNHp loaded cells (Figure 
15). This indicates first, an early high GEF activity that drives fast GppNHp loading of 
Ras, and second, proofed the presence of high GAP activity due to the fact that  
Ras-GppNHp is insensitive to GAP action. Taken together, the findings strongly 
supported the initial hypothesis that Ras deactivation is triggered by a timely gradual 
upregulation of GAP(s) activity in a background of continuous high nucleotide 
exchange. 
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Figure 15: GppNHp but not GTP promotes strong Ras activation at late time points of EGF 
stimulation.  
HeLa cells were permeabilised for the indicated time frames in the presence of GTP or GppNHp 
before (no stim.), 5 min or 20 min after EGF stimulation. Reactions were stopped by cell lysis and cell 
extracts were subjected to biochemical analysis of Ras and Erk activation. 
9.4 A feedback mechanism limits the duration of Ras activation  
As mentioned earlier, previous studies proposed negative feedback loops induced 
downstream of Ras by the MAPK pathway to terminate Ras activity (Langlois et al., 
1995a, b, Waters et al., 1995a, Waters et al., 1995b, Dong et al., 1996, Douville and 
Downward, 1997). To re-evaluate the negative feedback loop in the Ras/Erk pathway 
specific downstream kinase inhibitors or siRNA mediated knockdown approaches 
were used.  
9.4.1 Inhibition of MEK and Erk prolongs RasGTP level 
By using U0126, a highly specific MEK inhibitor, Erk phosphorylation was abolished 
and sustained Ras activation in HeLa cells was observed (Figure 16A). This finding 
suggests that an activation of MEK is involved in Ras deactivation. Similarly, this 
regulatory role of MEK was detected in MEF cells (Figure 16A). To look further 
downstream of MEK the cells were treated with FR108204, a potent Erk inhibitor. To 
monitor inhibition, an antibody specific for phospho-MAPK substrates was used. 
According to the results obtained with the MEK inhibitor the RasGTP level is 
prolonged through Erk inhibition (Figure 16B). Taken together, the Ras deactivation 
seems to be triggered via the MEK/Erk pathway, however the molecular mechanisms 
remained unknown. 
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In addition, an experiment in MEF cells which only express  
K-Ras was performed. These cells showed a similar time course of prolonged Ras 
activity in response of MEK inhibition (Figure 16C). 
 
Figure 16: Inhibition of the MEK/Erk pathway prolongs Ras activation. 
A) Resting HeLa or MEF cells were left untreated or treated with the MEK inhibitor U0126, followed by 
EGF stimulation and subjected to a Ras activity assay. B) HeLa cells treated  with the Erk inhibitor 
FR108204 or untreated were challenged with EGF and analysed for Ras and Erk activity pMAPK: Ab 
against the phosphorylated Erk consensus motif. C) Same experiment as in (A) performed in  
H-Ras-/-, N-Ras-/-, K-Raslox/lox MEFs expressing only K-Ras. The results are representative for at 
least three independent experiments. 
9.4.2 Inhibition of Rsk also leads to prolonged RasGTP accumulation 
Accumulating evidence suggests the existence of an Rsk-initiated negative-feedback 
loop that reduces Ras activation (Douville and Downward, 1997). To verifiy the 
possibility of Rsk activity being involved in modulating Ras activity a pan-Rsk inhibitor 
was used. Comparable to the inhibition of MEK or Erk, the block of Rsk activity using 
the BI-D1870 inhibitor led to increased RasGTP level (Figure 17A). qRT-PCR 
analysis revealed that Rsk 1 and 2 are the predominantly expressed isoforms in 
HeLa cells (Figure 17B). The siRNA-mediated depletion of Rsk1 and 2 mimicked the 
inhibitor effects in terms of prolonged of RasGTP accumulation (Figure 17C).  
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Overall, pharmacological inhibition as well as protein ablation of the MAPK-activated 
kinase Rsk caused a prolonged Ras activity, suggesting that the Ras deactivation is 
triggered by an Rsk-dependent feedback loop. However, these findings do not 
explain whether this process involves changes in the activity of GEFs, GAPs or both. 
 
Figure 17: Rsk inhibition leads to RasGTP accumulation at late EGF stimulation time point.  
A) Starved HeLa cells were pre-treated with the pan-Rsk inhibitor BI-D1870 and challenge with EGF 
for the indicated periods of time. The activation status of Erk and Rsk was monitored using  
phospho-site specific antibodies against Erk, Rsk and the phoshorylated Rsk/Akt-consensus motif 
(RXXS*/T*). Note that phosphorylation of the common Rsk and Akt substrate GSK3ß did not decline, 
possibly due to a feedback activation of Akt in response to Rsk inhibition. The results are 
representative for at least three independent experiments. B) Real-time PCR analysis of Rsk isoform 
expression in HeLa cells. C) Rsk1 and Rsk2 were simultaneously silenced via siRNA in HeLa cells 
followed by stimulation with EGF and biochemical analysis of Ras activation. 
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9.4.3 PI3K/Akt and p38 inhibition do not influence the transient Ras kinetics 
In addition to the MAPK pathway, Ras activity initiates other signalling cascades in a 
coordinated intracellular signalling network. With the intention to address whether the 
Ras deactivation is connected to one of these pathways the PI3K/Akt pathway was 
inhibited with Wortmannin and the p38 pathways with SB202190. The interruption of 
both effector branches did not affect RasGTP levels especially on late time EGF 
stimulation (Figure 18). Overall, after testing several pharmacological inhibitors within 
the Raf/MEK/Erk pathway the data disclose that the Ras deactivation originates from 
the MAPK-pathway, but the mechanisms behind the feedback loop are not known 
yet. 
 
Figure 18: EGF induces 
PI3K and p38 independent 
transient Ras activation.  
HeLa cells pre-treated with 
the MEK inhibitor U0126, 
PI3K inhibitor Wortmannin or 
the p38 inhibitor SB202190 
were challenged with EGF 
and subjected to a 
biochemical Ras activation 
assay.  
 
 
 
 
 
9.5 Sos activity is not affected by the feedback mechanism 
To clarify whether the MAPK pathway regulates Sos activity, GAP activity or both the 
nucleotide exchange assay was performed in the background of MEK (Figure 19A) 
and Rsk inhibition (Figure 19B). The chromatographic separation of Ras-bound 
GDP/GTP showed that the inhibitor treatment restored RasGTP accumulation at 20 
or 40 min post-EGF stimulation (Figure 19A/B). These findings were consistent with 
the western blot analysis of the RasGTP pull-down (Figure 16A and Figure 17A) and 
confirmed the existence of the feedback loop. Importantly, the nucleotide uptake rate 
was sustained at a high level following EGF stimulation and was not affected by the 
MEK/Rsk inhibition (Figure 19). Since Sos is the only relevant GEF expressed in 
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HeLa cells, these findings suggest that despite its phosphorylation Sos activity in 
terms of Ras activation is not affected by the MAPK pathway.  
 
Figure 19: Feedback deactivation of Ras is mediated via GAP up-regulation.  
A) Quiescent HeLa cells were pre-treated with U0126 as indicated, challenged with EGF and 
subjected to analysis of Ras nucleotide exchange. B) Same experiment as in (A) performed in cells 
treated with the pan-Rsk inhibitor BI-D1870. %GTP/(GDP +GTP) values were determined by 
densitometry and marked under the panel. 
9.6 NF1 is the responsible GAP within the feedback loop 
6 major classes of GAPs have been described in literature so far. To figure out which 
RasGAP is responsible for keeping the Ras activation transient their respective 
expression patterns were assessed by immunoblot detection (Figure 20A).  
Tagged-overexpression plasmids and siRNA mediated knockdown for NF1 served as 
controls for antibody specificity. The western blot analysis showed expression of 
NF1, DAB2IP and RASA1 also known as p120GAP. The GAP1 family members 
CAPRI, GAP1m and RASAL1 were poorly expressed endogenously, while the  
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plasmid-encoded overexpression was clearly detected. For GAP1IB4BP the 
immunodetection failed due to a non-functional antibody. 
Additional public gene expression datasets, which are placed at GEO (GSE6783), 
were checked for GAP expression levels. In this study serum-starved HeLa cells 
were stimulated with EGF for the indicated time intervals up to 480 minutes. By 
transcriptome analysis p120GAP (RASA1) and NF1 were detected in HeLa cells 
(Figure 20B) but likewise no appreciable levels of the GAP1 family members 
(GAP1m, GAP1IP4BP, CAPRI, RASAL) (Amit et al., 2007).  
 
Figure 20: Please see legend on following page. 
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Figure 20: Immunoblot detection and GEO search for GAP protein expression in HeLa cells  
A) Western blot analysis showing GAP expression level in HeLa cells. Red arrows mark 
overexpressed proteins, black arrows mark predicted mobility level of endogenous protein.  
B) The cervical carcinoma HeLa cells gene expression datasets from the GEO dataset ID GSE6783 
with the platform ID GPL96 were used to identify expression of GAP species. In this study  
serum-starved HeLa cells were stimulated with EGF for the indicated time intervals up to 480 minutes 
(Amit et al., 2007). Depicted are the expression for the both detected GAPs NF1 and RASA1. 
9.6.1 siRNA mediated NF1 knockdown prolongs RasGTP accumulation 
All three GAPs, NF1, p120GAP and DAB2IP, were abundant in HeLa cells during 
EGF stimulation and no changes were detected in their expression level (Figure 21A, 
lower panels). In order to address the involvement of each of the three GAP proteins 
in Ras deactivation, individual knockdowns were performed by using respective 
siRNA. The knockdown of the p120GAP (RASA1) showed no remarkable changes 
on RasGTP levels compared to untransfected cells (Figure 21A). Further, it was 
verified that the siRNA treatment had no influence on the integrity of the MAPK 
mediated feedback mechanism by combining siRNA knockdown with MEK inhibitor 
treatment. Likewise, the DAB2IP knockdown did not affect the decrease in RasGTP 
level at late time points after EGF stimulation (Figure 21B). In contrast, NF1 depletion 
led to sustained RasGTP level similar to the effects of MEK inhibition (Figure 21C). 
Moreover, NF1 knockdown showed no changes on investigated GAP levels. This 
result was reproduced in HEK293T cells stably transfected with shRNA for NF1 
(Figure 21D). 
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Figure 21: Feedback mediated stimulation of NF1 mediates Ras deactivation. 
A) EGF induced Ras activation in HeLa cells subjected to previous siRNA-mediated silencing of 
RASA1. siRNA transfected cells were additionally treated with the MEK inhibitor U0126. B) DAB2IP-
silenced HeLa cells were treated with EGF for indicated time points. C) Same experiment as in (B) 
performed in NF1-silenced HeLa cells. D) Time course of EGF-driven Ras activation in HEK293T cells 
and a derivative line with stable shRNA-mediated knockdown of NF1. The results are representative 
for at least three independent experiments. 
9.6.2 NF1 acts in a background of high nucleotide exchange activity 
Previous experiments displayed similar prolongation of RasGTP formation after 
MEK/Rsk inhibition and NF1 knockdown. To understand the precise role of NF1 at 
the time where the Ras level declines, the permeabilisation assay to measure the 
GTP uptake by Ras was performed in NF1 depleted HeLa cells. On the one hand, 
the TLC figured out that the RasGTP level is sustained after 20 min EGF stimulation 
upon NF1 knockdown, similar to the western blot of the Ras activity assay. On the 
other hand, the nucleotide exchange is continuously proceeding, indicating that the 
GEF activity is not affected by NF1 depletion.  
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Hence, NF1 is the major regulatory protein that decreases RasGTP levels at late time 
points of growth factor signalling. 
 
Figure 22: NF1 activation mediated Ras deactivation 
HeLa cells subjected to siRNA mediated silencing of NF1 were challenged with EGF. Cells were 
permeabilised at 0, 5 and 20 min after EGF stimulation and processed for the analysis of nucleotide 
exchange on Ras. Nucleotides associated to Ras-IPs were additionally eluted from Ras and separated 
via thin layer chromatography (TLC, on the right). %GTP/(GDP +GTP) values were determined by 
densitometry and marked under the panel. 
9.7 NF1 harbours conserved Erk and Rsk phosphorylation sites  
The former results unveil an engagement of Rsk kinase signalling likewise NF1 in the 
downregulation of RasGTP level after growth hormone receptor signalling. At 
present, little is known about the regulation of NF1 and its precise role in controlling 
Ras signalling pathways. In order to elucidate a biochemical link between Rsk 
signalling and NF1 the NF1 protein sequence were checked for specific Erk and Rsk 
phosphorylation sites. The multiple sequence alignment of human NF1 with the NF1 
amino acid sequence from a variety of other species revealed only one MAPK motif 
(PxSP) in humans at the C-terminal end from amino acid 2758 to 2761 (Figure 23). 
This phosphorylation motif is highly conserved amongst mammals (Homo sapiens, 
Mus musculus and Rattus norvegicus) and Drosophila melanogaster. In contrast, 
NF1 contains three Rsk phosphorylation site consensus motifs (RxRxxS/T), which 
are conserved within mammals but not in fly. 
To investigate the possibility of direct phosphorylation of NF1 by Erk two different 
antibodies directed against the phosphorylated Erk substrate motif or  
phospho-Threonine-Proline were used, to detect a signal in NF1 IPs 20 min  
post-EGF stimulation. Since NF1 is a huge protein with innumerable phosphorylation 
sites, additional phosphorylations after EGF stimulation are difficult to predict in 
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western blot analysis and no changes were detected within the Erk phosphorylation 
sites (data not shown). To this end, mass spectrometry (MS) analysis was performed 
by Katharina Wolff in cooperation with Dr. K-H. Gührs (Leibniz Institute on Aging, FLI, 
Jena). For MS analysis, GFP-NF1 was overexpressed in HeLa cells. Notably, many 
reported studies (Martin et al., 1990, Klose et al., 1998) used only partial domains of 
NF1 for their analysis based on complications to clone full-length NF1 (f.e. GAP 
domain). Strikingly, Yan Cui from the Leibniz Institute on Aging in Jena was able to 
clone the full length NF1 with few modifications in the cDNA and kindly provided us a 
GFP tagged NF1 plasmid for transient overexpression. GFP-NF1 was purified by 
immunoprecipitation and separated by SDS-PAGE. Silver stained protein bands 
containing GFP-NF1 or candidate interactors were excised and subjected to 
proteolytic trypsin in-gel digestion. Because of weak NF1 overexpression and low 
capacity to immunoprecipitate tagged or untagged NF1 the MS analysis and the 
attempt to directly compare the phosphorylation sites at different EGF stimulation 
time points was not possible (extensive described in the Master thesis of Katharina 
Wolff). Similarly, efforts to mutate the Erk phosphorylation site Thr2738Ala were not 
feasible. Thus, the question if Thr2738Ala-mutated NF1 may abrogate Ras 
deactivation in HeLa cells depleted for their endogenous NF1 remained open. 
Moreover, defining a direct Rsk phosphorylation on NF1 with a phosphorylated 
Rsk/Akt-consensus motif (RXXS*/T*) antibody in HeLa lysates was not achieved.  
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Figure 23: Multiple sequence alignment of NF1 proteins from different species  
The alignment depicted shows sequence regions containing possible Erk and Rsk specific 
phosphorylation sites. Erk sites are highlighted in blue and Rsk sites in yellow. Alignment was 
generated by the online software tool Clustal Omega at http://www.ebi.ac.uk/Tools/msa/clustalo/. 
9.8 Spred proteins and Ubiquitin are possible NF1 interaction partners 
Despite few NF1 interaction partners have been identified during the last decade the 
cellular role of NF1 remains unclear. Stowe et al. (Stowe et al., 2012) showed that 
Spred1 is an NF1 interacting protein and that NF1 is necessary for Spred1's 
inhibitory function as a negative regulator of the Ras/MAPK pathway. They showed 
that Spred1 binding induces the plasma membrane localisation of NF1. Recently 
suppressor effects of Spred2 on the Ras–MAPK pathway were confirmed as well 
(Nobuhisa et al., 2004). In order to decipher if Spred proteins are involved in a NF1 
containing Ras deactivation feedback loop, Katharina Wolff could verify the 
interaction of overexpressed Flag-tagged Spred1 and 2 with NF1 by  
co-immunopreciptiation (IP). Of note, precipitating for NF1 revealed only interaction 
with Spred2 but not with Spred1 (data not shown). To establish the role of Spred 
proteins on RasGTP levels a usual Ras activity assay was performed in HeLa cells 
overexpressing Flagged-Spred proteins. Cells with high levels of Spred2 showed 
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diminished RasGTP level while keeping a transient kinetic following EGF stimulation 
(Figure 24). Similar results could be achieved by overexpression of Spred1 (data not 
shown). By performing these experiments in the presence of pharmacological MEK 
inhibition, it was shown that the feedback loop itself was not abolished by the 
overexpression of Spred proteins or the transfection procedure. Furthermore, a 
decreased Sos activity dependent on Spred2 overexpression was obtained to reduce 
RasGTP level (Figure 24B). In conclusion, Spred2 decreases the GEF activity rather 
than inducing GAP activity. Based on these findings we stopped focusing to identify 
the role for Spred proteins as mediators of Rsk-dependent NF1 activation.  
 
Figure 24: Spred2 overexpression reduces RasGTP levels and nucleotide exchange activity. 
A) HeLa cells transfected with Flag-Spred2 were stimulated with EGF in the presence or absence of 
the MEK inhibitor U0126 and processed for RasGTP analysis and Flag-Spred2 expression. 
B) Nucleotide exchange assay in HeLa cells transfected with Flag-Spred2. Cells were permeabilised 
prior to or 5 min after EGF stimulation and processed for the analysis of nucleotide exchange on Ras. 
Nucleotides associated to Ras-IPs were additionally eluted from Ras and separated via thin layer 
chromatography (TLC, on the right). %GTP/(GDP +GTP) values were determined by densitometry and 
marked under the panel. 
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A previous report showed that NF1 is destabilised by growth factors via the 
proteasome and that ubiquitin can interact with NF1. It is likely that these features 
play a role in the proposed Ras feedback loop. To investigate the role of ubiquitin 
Katharina Wolff overexpressed HA-tagged ubiquitin and performed the same 
experimental set-up as described before. However, we could not detect any 
ubiquitination on NF1 in HeLa cells during EGF stimulation (data not shown). Taken 
together it is unlikely that ubiquitin affects NF1 activity. 
9.9 MEK inhibition increases Ras nanoclustering 
Previous studies have established that the distribution of Ras molecules to distinct 
micro- and nanodomains at the inner leaflet of the plasma membrane (PM) has an 
impact on the downstream signalling capacity of Ras (Prior et al., 2001, Prior et al., 
2003). These observations raise the possibility that Ras itself influences the feedback 
signal. One opportunity could be that MEK/Erk feeds back on the nanocluster 
distribution of Ras making it more accessible to NF1 action. In this context a 
cooperation with Prof. Ian Prior from the University of Liverpool was initiated. His 
group has great experience in imaging Ras signalling domains by electron 
microscopy to characterise the dynamic of Ras. The preliminary data performed by 
Alison Beckett the technical assistant in the Prior lab demonstrated that MEK1/2 
inhibition via UO126 or combined ablation of MEK1 and MEK2 via siRNA increased 
the H-Ras nanoclustering in HeLa cells independently of EGF stimulation (Figure 25). 
Based on a work stay in Liverpool further nanocluster experiments at 5 min and 20 
min post-EGF were conducted to confirm the impact of MEK and NF1 knockdown on 
Ras nanoclustering at the PM of HeLa cells but the data show inconsistent results 
and are not shown here. Finally MEK inhibition affects the distribution of Ras to 
microdomains and nanoclusters but we don’t know yet how this distribution is 
affected in response to growth factors.  
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Figure 25: Loss of MEK activity alters H-Ras nanoclustering.  
A) Immuno-gold labelling of GFP-H-Ras on isolated plasma membranes reveals Ras nanocluster 
distributions. B) Ras nanocluster distribiution analysed by spatial statistics. L(r)-r values above 1.0 
indicate significant clustering. H-Ras nanoclustering (♦) is increased upon loss of MEK activity (◊) by 
either MEK1/MEK2 inhibition or knockdown. Bar = 50 nm. Figure created by Alison Beckett. 
9.10 Modelling of a GAP-mediated feedback 
The observations suggest that an Rsk dependent feedback regulates Ras 
deactivation via activating NF1 GAP activity. To get some testable predictions that 
could give more insight Manuel A. Esparza-Franco modeled the pathways and 
potential effects on GEF and GAP blockage. The minimal mathematical models 
described the feedback stimulation of GAP activity in the presence of continuously 
high GEF activity. All values they used are based upon published data with the 
exception of the NF1 parameters where no data was available. The assumptions he 
has made and the outputs from these models are outlined in the next sections. 
9.10.1 Late time GAP blockade via Erk inhibition 
On the assumption that Rsk promotes NF1 activity, they concluded that the adding of 
an Erk inhibitor (FR180204) blocks the GAP activity in the cells. Therefore the first 
model mimics the GAP blockage at late stimulation and predicts a fast increase of 
RasGTP levels (Figure 26A). To validate this prediction Erk was inhibited acutely at 
35 min post-EGF treatment for which re-raising RasGTP levels were detected (Figure 
26B). Thus, inhibition of Erk signalling after GAP mediated Ras inactivation, 
increases RasGTP levels most likely due to continuous GEF activity of Sos in the 
presence of abolished GAP activation. 
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Figure 26: Late time Erk inhibition blocks the GAP activity and increases the RasGTP level. 
A) Model simulating late time Erk inhibition. In the model the concentration of RasGTP, the receptor-
GEF complex (R-GEF) and GAP activity are plotted against the time of EGF stimulation. Receptor-
GEF complex mimic the activity of Sos. B) Ras activation was initiated in HeLa cells by 10 ng/ ml EGF 
addition and Erk activity was quenched 35 min later with 50 µM FR180204. Samples were processed 
in a RasGTP activation assay. Figure A created by Manuel A. Esparza-Franco. 
9.10.2 Late time GEF blockade via EGFR inhibiton 
In the second model they simulated a late time GEF activity blockade by interruption 
the pathway upstream of Ras to approve a GAP-mediated feedback. For this purpose 
they used an EGFR inhibitor (AG1478), which is supposed to obstruct the EGFR 
triggered activity of Sos. Theoretically, late time RasGTP levels are triggered by GAP 
activity in the background of high GEF activity and thus a block of the high GEF 
activity at this time point predicts a further drop in RasGTP levels (Figure 27A). To 
proof this hypothesis in an experimental set up HeLa cells received an EGFR 
inhibitor 35 min post-EGF stimulation. The predicted drop in the anyway low RasGTP 
level was observed by the following Ras activity assay (Figure 27B). Erk activity 
declined in parallel as a consequence of EGFR inhibition. To validate that EGFR 
inhibition reduces the remaining nucleotide exchange activity a permeabilisation 
assay was accomplished under these conditions. Importantly, exchange curve of 
EGFR inhibitor treated HeLa cells was similar to the basal condition despite the 
continuous EGF stimulation (Figure 27C). This highlights the simultaneous action of 
Sos GEF and GAP proteins on Ras following growth factor receptor stimulation, with 
Sos being the major driving force and GAP proteins representing the physiological 
brake. Whereas Sos activity in the sense of Ras activation seems to be primarily 
regulated upstream of Ras, GAP activity are highly correlative with MAPK, e.g. Rsk 
signalling. 
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Figure 27: Late time EGFR inhibition blocks the 
GEF activity and decrease the RasGTP level.  
A) Model simulating late time EGFR inhibition. In the 
model the concentration of RasGTP, the receptor-
GEF complex (R-GEF) and GAP activity are plotted 
against the time of EGF stimulation. Receptor-GEF 
complex mimic the activity of Sos. B) HeLa cells in 
all assay points were simultaneously stimulated with 
10 ng/ ml EGF. 35 min post-EGF Sos activity was 
quenched by the addition of an EGFR inhibitor  
(250 nM AG1478). C) Cells were permeabilised prior 
to or 5 and 20 min after EGF stimulation or treated in 
addition for 5 min with AG1478. All samples were 
processed for the analysis of nucleotide exchange 
on Ras. Figure A created by cooperator Manuel A. 
Esparza-Franco (Warwick, UK). 
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10 Discussion 
Growth factor induced Ras-MAPK pathway activation leads to cell proliferation and 
differentiation. Aberrant Ras signalling can be found in many malignancies as nearly 
30% of all human cancers are due to a point mutation in RAS (Bos, 1989). Because 
of its important role in carcinogenesis Ras itself as well as the upstream and 
downstream signalling molecules are prominent targets for anticancer therapy. The 
last three decades of intensive research yielded profound structural information of 
Ras and its regulators (GEFs and GAPs), including detailed information about 
catalytically Ras/GAP/GEF interactions (Scheffzek et al., 1997, Wittinghofer et al., 
1997, Ahmadian et al., 2003). Despite constant efforts, the treatment of Ras driven 
cancers has remained largely ineffective (Cox et al., 2014). The complexity and the 
huge amount of feed-forward and feedback mechanisms often lead to drug 
resistance and hence combinatorial drug treatment is the method of choice (Vera et 
al., 2010). Nevertheless, the targeting of Ras downstream signalling effectors, such 
as Raf or MEK inhibition has been the most favourable approach, even if their 
mechanism of actions is far from being completely understood. 
Growth factors induce a transient Ras activation to drive cells into the cell cycle and 
evoke cell proliferation. The activation of Ras is triggered through increased 
nucleotide exchange activity on Ras. The termination of the Ras signal can be 
caused by three theoretical ways (Figure 28): First, via GEF inactivation while GAPs 
play only a minor role to keep a steady-state of Ras-bound GTP hydrolysis. Second, 
via GAP activation in order to counteract the action of GEFs or third, a combination of 
both. Nevertheless it is important to switch off Ras rapidly after growth factor 
stimulation for the sake of transient (i.e. mitogenic) signal transmission. One major 
aim of this thesis was to reveal the mechanisms behind Ras deactivation and the 
underlying signalling network.  
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Figure 28: Ras activation/deactivation can occur via changes in GEF and/or GAP activity. 
Growth factor induced Ras activation is of transient nature. Further, Ras activation is known to be 
mediated by GEF activation. However, various models exist accounting for Ras deactivation in 
response to growth factors: 1. downregulation of GEFs, 2. activation of GAPs or 3. A combination of 
both (the activity of GAPs and GEFS is symbolised by the thickness of the arrows). 
10.1 Ras activation is of transient nature 
The kinetics of Ras activity were approached upon growth factor stimulation in two 
different cell types by a conventional Ras activity assay, measuring the RasGTP 
levels at steady state. In line with previous studies (Muroya et al., 1992, Traverse et 
al., 1992, Langlois et al., 1995b), growth factor stimulation induced a rapid increase 
in RasGTP levels. Interestingly, Ras activity was observed to decline back to basal 
levels already after several minutes depending on the stimulus and the cell typ. The 
termination of the Ras signal was achieved despite the continuous stimulation of 
receptor tyrosine kinase activity. In accordance with Waters et al. (Waters et al., 
1996) we detected a persistent EGFR phosphorylation arguing against the possibility 
of fast EGFR degradation or dephosphorylation triggering the transient Ras 
activation. In addition to the continuous upstream signalling, the activity of the 
downstream signalling visualised by phosphorylated Erk, is also sustained indicating 
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ongoing kinase activity downstream of Ras apart from the strong decline in RasGTP 
levels.  
Many publications report considerations about growth factor and mitogen mediated 
Ras activation catalysed by activation of GEF (mainly Sos) by measuring the 
nucleotide uptake in permeabilised cells (Table 15) (Buday and Downward, 1993b, a, 
Graziani et al., 1993, Medema et al., 1993). The data presented within this thesis 
confirmed the observation that EGF triggers Sos accelerating GTP-loading of Ras, 
since an enhanced nucleotide uptake was measured in HeLa and MEF cells after 
stimulation. Notably, the permeabilisation assay was advantageous enabling the 
measurement of GEF activity at pre-steady state.  
At the bottom line Ras activation is generated by GEF activation as supposed before. 
However, we cannot exclude that GAP inactivation may also play a role in EGF 
induced Ras activation. Generally. direct assessment of GAP activity is 
experimentally unfeasible. To reveal the influence of GAPs on basal Ras activity we 
performed a Ras pulldown experiment in resting cells with a single or combined GAP 
knockdown and identified a marginal increase in RasGTP levels. This experiment 
gave us elementary evidence that Ras activation is not based on GAP inhibition and 
that RasGAPs possibly act first of all downstream of growth factor stimulation to 
downregulate Ras.   
It has been hypothesised that the negative feedback on Sos initiated downstream of 
Ras, shapes the dynamics of RasGTP accumulation (Langlois et al., 1995a, Rozakis-
Adcock et al., 1995, Waters et al., 1995a, Corbalan-Garcia et al., 1996b, Douville and 
Downward, 1997). However, a comprehensive discussion including the particular role 
of GAPs was not addressed within this reports. In cooperation with Graham Ladds a 
mathematical model was created to simulate the involvement of GAPs. The obtained 
model supposed that the fast decay of RasGTP after stimulation can occur in the 
background of high GAP activity only. In respect of lower GAP activity the RasGTP 
level would stay high or drop just slowly because of the low intrinsic hydrolysis rate. 
Likewise several computational models described earlier predicted the need of  high 
GAP activity (Wolf et al., 2007). Moreover simply switching off Sos was considered 
as insufficient to efficiently deactivate Ras without invoking high GAP activity 
(Markevich et al., 2004). As the available data for RasGAPs is limited and the direct 
GAP activity measurements are technically unfeasible, a great interest exists to 
profoundly understand the underlying biochemical mechanisms.  
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Table 15: Studies documenting a stimulation of nucleotide exchange on Ras in permeabilised 
cells in response to growth factors and mitogens.  
Table is adapted from a review article (Hennig et al., 2015). 
10.2 Sos phosphorylation does not reduce nucleotide exchange activity on 
Ras 
In case of Sos mediated Ras activation it is published that Sos is recruited to the 
plasma membrane by the RTK adapter protein Grb2 to catalyse the GDP/GTP 
exchange on Ras (Li et al., 1993, Rozakis-Adcock et al., 1993). In theory, attenuation 
of the Ras signal in the cell could be easily achieved by the plasma membrane 
detachment of Sos, thus abolishing proximity of Sos to Ras. In agreement with this 
hypothesis, studies reported a MEK or Erk-dependent Sos phosphorylation early 
after growth hormone receptor stimulation, which leads to the dissociation of Sos 
from Grb2 (Waters et al., 1995a, Waters et al., 1995b, Dong et al., 1996, Zhao et al., 
1998). Further it has been speculated that Grb2-Sos dissociation acts inhibitory on 
the Ras nucleotide exchange and in this way modulates the duration of Ras 
activation (Langlois et al., 1995a, Rozakis-Adcock et al., 1995, Waters et al., 1995b, 
Corbalan-Garcia et al., 1996b, Porfiri and McCormick, 1996, Kamioka et al., 2010). In 
addition to Erk and MEK, p90 Rsk was supposed to be a further mitogen activated 
kinase targeting Sos (Douville and Downward, 1997). Furthermore, Roux et al. (Saha 
et al., 2012) hypothesised that Rsk dependent Sos phosphorylation creates  
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14-3-3 binding sites and therefore negatively regulates MAPK signalling. However, 
the GEF activity of Sos was never tested in these studies. In our work we confirmed 
the phosphorylation of Sos after growth factor stimulation. Moreover, Sos 
phosphorylation was blocked by pharmacological inhibition of MEK and Erk by the 
use of U0126 (Duncia et al., 1998) and FR108204 (Ohori et al., 2005), respectively. 
Though, if the pan-Rsk inhibitor BI-D1870 (Sapkota et al., 2007) was applied 
phosphorylation of Sos remained uneffected. In conclusion these observations 
revealed that the EGF mediated Sos phosphorylation is MEK/Erk-dependent, 
nonetheless Rsk-independent.  
The Sos-negative feedback models described in literature are conclusive but have 
never been proved experimentally, because measuring Sos driven nucleotide 
exchange in live cells is experimentally challenging. Similar to previous studies 
(Buday and Downward, 1993b, Medema et al., 1993, Rubio et al., 2003), the 
nucleotide exchange at pre-steady state was measured by using the 
permeabilisation-based approach. Surprisingly, the nucleotide exchange rate on Ras 
was continuously high as well at the time point where RasGTP amount dropped 
down. This result disproved the previous observations of the MAPK-mediated 
negative feedback inhibition of Sos activity, at least in the case of the particular 
cellular models analysed. Taken together, the results gave evidence for a growth 
factor dependent Sos phosphorylation, but these phosphorylation had no influence 
on the Sos nucleotide exchange activity, indicating that regulation of Sos activity is 
dispensable for the Ras feedback inhibition.  Furthermore, they point to GAP 
activation as the mechanism of signal termination. These results are in line with 
previous publications demonstrating that neither the dissociation of Sos from Grb2 
nor the phosphorylation of Sos correlate with Ras activity state (de Vries-Smits et al., 
1995, Corbalan-Garcia et al., 1996a). Growth factor dependent feedback 
phosphorylation of Sos potentially acts on different signalling pathways, that may be 
related to the control of Rac and the actin cytoskeleton (Sini et al., 2004).  
Conclusively, the rapid decline of RasGTP level does not rely on the inhibition of Sos 
activity. This statement is supported by the observation that permeabilised HeLa cells 
loaded with non-hydrolysable GTP displayed sustained RasGTP levels in contrast to 
cells loaded with GTP which is sensitive for GAP action. In addition, this experimental 
set-up proved the presence of RasGAP activity during Ras deactivation. 
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10.3 Ras deactivation is driven by Rsk-dependent feedback activation  
In comparison to previous reports, our results demonstrated that regulation of the 
nucleotide exchange activity of Sos is not the major driver of the inactivation of Ras. 
Nevertheless, several reports claimed feedback regulation of the MAPK cascade 
(Brightman and Fell, 2000, Cirit et al., 2010, Kamioka et al., 2010). In accordance, 
our own findings showed that Ras activity is sustained after MEK/Erk/Rsk inhibition, 
which indeed presumes a feedback loop operating via MEK/Erk/Rsk in order to 
downregulate Ras activity.  
In regard of the fact that the existing Ras isoforms differ biologically and functionally 
(Castellano and Santos, 2011), we could show that the feedback proceeded in MEFs 
expressing K-Ras but not N-Ras and H-Ras. So it is suggested that the feedback is 
maintained at least in the presence of K-Ras.  
Moreover, the permeabilisation assay did not reveal any changes in the nucleotide 
exchange activity during the MEK or Rsk inhibitor treatment, indicating that the MAPK 
mediated phosphorylations on Sos do not influence its GEF activity. Notably Rsk 
inhibition interrupts the feedback deactivation of Ras without affecting the 
phosphorylation state of Sos, providing further evidence that Sos phosphorylation 
does not correlate with the fast decline in RasGTP level.  
In accordance with other expression studies (Carriere et al., 2008) we detected Rsk1 
and Rsk2 as the main isoforms in HeLa cells. To strengthen the assumption that 
Rsk1/2 are mediators of GAP feedback activation, a combined knockdown of Rsk1 
and Rsk2 was performed and showed an equally prolonged Ras activation. In 
agreement with a Rsk mediated Erk inhibition in Drosophila (Kim et al., 2006), our 
results corroborate the hypothesis that the growth factor stimulated feedback loop is 
propagated via Rsk1 and Rsk2. 
p38 kinase is most strongly activated by proinflammatory cytokines (Lee et al., 1994) 
and less efficiently by Ras (Lin et al., 1995). Nevertheless the p38 pathway was 
shown to provide negative feedback for Ras proliferative signalling as well (Chen 
2000). Hence, it is likely that even this moderate activation could have an important 
impact on Ras signalling. Solely the inhibition of MEK/Erk or Rsk and not PI3K or 
p38, resulted in prolonged Ras activation, further demonstrating that the PI3K 
pathway is not involved in the EGF-stimulated feedback on Ras. The concomitant 
detection of enhanced phospho-Akt level after MEK and Rsk inhibition was possibly 
caused by a normal, compensatory cell response after Rsk inhibition, since Rsk and 
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Akt share substrate specificity. This reflects the complexity of MAPK signalling 
including several pathway crosstalks, which amplifies the mitogenic stimuli (Kiyatkin 
et al., 2006).  
The fact that the kinases Rsk1 and Rsk2 stimulate the GAP activity in a kind of a 
positive feedback loop to terminate Ras activation is a totally new paradigm, 
especially due to the reason that active Rsk enzymes are mainly described to act 
further downstream.  
Ultimately, Ras itself engages a GAP system for the purpose of restraining the 
duration of its own activation in response to growth factors. That implies that 
RasGAPs play a precise role in Ras deactivation.  
10.4 NF1 in the agonist-dependent control of Ras deactivation  
The experimental and modelling data show that RasGAP activity is induced in the 
context of a feedback loop initiated by activated Ras and modulated by Rsk1 and 
Rsk2. Results obtained from a proteomic screen (Amit et al., 2007) and western blot 
analysis validated the abundant expression of p120GAP, NF1 and DAB2IP in EGF 
stimulated HeLa cells. For this reason the efforts were focused on p120GAP, NF1 
and DAB2IP. The negligibility of the GAP1 family members was corroborated by 
immunoblotting results showing very low protein levels in the analysed cell model. In 
addition this was supported by the fact that EGF is a weak PLC activator evoking 
poor Ca2+ release, which consequently leads to less GAP1 activity. SynGAP proteins 
were equally unlikely candidates because they are a known as neuronal restricted 
GAP species (Kim et al., 1998).  
To identify the responsible RasGAP we monitored the EGF permitted Ras kinetic in 
GAP diminished HeLa cells. The knockdown of NF1 alone sustained RasGTP level 
after growth factor stimulation, which was comparable to the level after Rsk inhibition. 
This experiment provided the first evidence for NF1 functioning as the RasGAP 
responsible for attenuating Ras activity in mitogenic signalling.  
The chromatograms from the permeabilisation assay in NF1 knockdown cells 
showed prolonged RasGTP in the presence of an unaltered nucleotide exchange, 
comparable to the rate obtained using the Rsk inhibitor. Hence, NF1 is a likely 
candidate to deactivate Ras via an Rsk-dependent feedback mechanism. It has been 
known for a long time that NF1 is ubiquitously expressed and its tumour suppressor 
activity is supposed to base on the ability to downregulate RasGTP level via the 
RasGAP domain (Bollag et al., 1996, Guha et al., 1996, Klose et al., 1998).  
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Now in this study it is firstly demonstrated that NF1 possesses crucial functions in 
growth factor signalling. Future work may address the identification of precise 
biochemical links. Three plausible mechanisms may be suggested to regulate NF1 
activity in growth factor controlled Ras deactivation and will be discussed in the next 
sections. 
10.4.1 Direct NF1 phosphorylation as possible regulation mechanism 
NF1 is a large protein consisting of 2,818 amino acids with several phosphorylation 
sites. Firstly, a potential mechanism may involve Rsk kinase mediated 
phosphorylation of NF1 to increase its GAP activity in order to drive RasGTP 
hydrolysis (Figure 29). The EGF dependent NF1 phosphorylation level was tested by 
using different approaches. First, a modest mobility shift was detected after EGF 
stimulation on standard western blots. To improve the detection various methods 
were applied. 1) A special, modified phosphate-binding acrylamide using 
manganese(II) ion-aided complex formation which acts as a selective phosphate tag 
and enhanced the mobility shift in western blots. 2) An agarose based approach 
(PhostagTM Agarose) where di-nuclear zinc(II) complex is attached as a selective 
phosphate-binding tag molecule. Technically this strategy is based on an immobilised 
metal affinity chromatography. Both approaches were insufficient to yield conclusive 
findings (data not shown), either due the large protein size of NF1 or vast extent of 
phosphorylation sites that possibly mask Rsk-dependent phosphorylation events. 
Furthermore, difficulties in molecular manipulation of the NF1 coding sequence were 
a hurdle for approaches such as site-directed mutagenesis to substantiate the 
specific phosphorylation site. Analysis of mass spectra was not successful to 
determine any phosphorylation event within the three Rsk-consensus motifs 
(RxRxxS/T) because of dissatisfactory quality of the spectra. Finally, more rigorous 
characterisation of NF1 including approaches like immunoprecipitation or stably 
transfected mutants may aid in revealing interaction partners and growth-factor 
induced modifications to this large RasGAP. 
10.4.2 NF1 regulation via unknown intermediate proteins 
A second possibility is that one or more unknown protein(s) get engaged by Rsk to 
regulate NF1 activity (Figure 29). Many substrates have been defined for Rsk (Frodin 
and Gammeltoft, 1999) which adds further complexity to this effector pathway.  
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Efforts to screen for Rsk-phosphorylated proteins acting on NF1 after growth factor 
stimulation were inconclusive as the huge number of candidates precluded further 
work in this direction. In contrast, literature proposes various proteins as  
NF1-interacting proteins (Ratner and Miller, 2015).  
a) Spred proteins as negative regulator of the MAPK pathway and NF1-binding 
proteins 
Evidence that Spred proteins are possible candidates derives from the fact that the 
Legius syndrome, a rasopathy and developmental disorder caused by germline 
mutations in the Spred1 gene, has an overlapping phenotype (facial abnormalities, 
learning disabilities, pigmental changes) with neurofibromatosis type 1 (Brems et al., 
2007, Pasmant et al., 2009, Spurlock et al., 2009). In this respect a common 
regulatory mechanism seems likely. Further evidence along this line, is given by 
another publication which showed that NF1 is a Spred1-interacting protein and 
suggested that this interaction is essential for the inhibitory function of both Spred1 
and NF1 on Ras (Courtois-Cox et al., 2006, Stowe et al., 2012).   
Spred proteins are known to directly negate the Ras/MAPK pathway after various 
mitogenic stimulations (Bundschu et al., 2007, Ullrich et al., 2011). The hypothesis of 
Rsk mediated phosphorylation of Spred leading to increased NF1 GAP activity 
seems conclusive. Reports about tyrosine phosphorylation of Spred exist (Mason et 
al., 2004, Lock et al., 2006), whereas nothing is known about Ser/Thr 
phosphorylation. Finally, it is conceivable that the phosphorylation of Spred by 
protein kinases is a possible mechanism to regulate Spred activity (King et al., 2005). 
However, Spred proteins exhibit neither an Erk phosphorylation site nor an Rsk 
phosphorylation motif weakening a potential connection to Rsk. 
Furthermore, it has been reported that Spred proteins are able to act upstream and 
downstream of Ras. Studies proposed that the mode of action is downstream of Ras 
where Spred inactivates the MAPK pathway by suppressing the phosphorylation and 
activation of Raf. In this context, Wakioka and co-workers described an enduring 
Spred-Ras interaction. However, they published that the interaction has no influence 
on Ras activation or the Raf plasma membrane localisation (Wakioka et al., 2001). In 
contrast, King et al. (King et al., 2005) evidenced that Spred regulates Ras upstream 
by affecting the RasGTP levels, although the detailed mechanism have not been 
clarified.  
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An additional level of Ras-independent regulatory mechanisms is the localisation of 
Spred1 in cholesterol-rich membrane rafts/caveoli fractions and that Spred1 inhibits 
Erk activation in conjunction with Caveolin-1, a main component of the caveolae 
plasma membranes (Nonami et al., 2005).  
As observed by Ras activity assay, Spred2 overexpression facilitates a considerable 
reduction in RasGTP levels. Spred2 overexpression thereby affects the Sos activity 
rather than GAP activity demonstrated by diminished nucleotide exchange activity in 
the permeabilisation assay. Thus, Spred2 contributes to the regulation of Ras activity 
but not in the context of NF1 mediated Ras downregulation.  
At least Spred proteins are signalling inhibitors with proposed tumour suppressive 
functions, but we found no correlation between Spred and NF1 GAP interaction and 
Ras deactivation after growth factor stimulation. We still cannot answer the question 
if the negative regulator Spred is involved in a fundamental mechanism of negative 
feedback or a kind of fine-tuning of the signal. The data regarding Spred proteins 
leave room to perform further experiment to unveil the emerging role regarding Sos 
inhibition.   
b) Is the EGF induced NF1 activity regulated by ubiquitin-dependent proteolysis? 
Ubiquitin ligases have been described as NF1- interacting proteins. It is known that 
the binding of ubiquitin molecules to the target protein induces rapid degradation by 
the 26S proteasome and that this degradation process is involved in diverse cellular 
processes (Kornitzer and Ciechanover, 2000). To observe if the protein level of 
disposable NF1 is responsible for transient Ras activation the NF1 protein level was 
detected by western blot analysis. NF1 immunoblots showed high NF1 abundance at 
every time point tested during EGF stimulation. This observation is inconsistent with 
a publication claiming that Ras dynamic is regulated as a consequence of Erk 
mediated NF1 accumulation (Cichowski et al., 2003, Tan et al., 2011, Hollstein and 
Cichowski, 2013). Also in Yeast it was shown that an ubiquitination pathway can 
negatively regulate NF1 (Phan et al., 2010). Further, it was postulated that 
ubiquitination functions as mediator of signal transduction in addition to its role in 
cellular proteolytic processes (Pickart and Eddins, 2004). Ubiquitin overexpression 
studies performedin HeLa cells did not confirm NF1 ubiquitination even following 
growth factor stimulation. These findings do not confirm the theory of regulating Ras 
activity via ubiquitination and proteolysis as well as fast growth factor induced  
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re-elevation of NF1 at least in the case of the cell types studied here. Moreover, 
considering the large size of NF1, it is difficult to conceive the possibility of rapid NF1 
synthesis and degradation as a regulatory mechanism of Ras deactivation.  
10.4.3 EGF dependent NF1 and Ras distribution  
Previous studies argued that also membrane targeting of GAPs can influence the 
catalytic activity of RasGAPs (Huang et al., 1993, Sot et al., 2013). As mentioned 
before, Spred1 is able to attract NF1 to the plasma membrane and thus in turn may 
downregulate Ras activity (Stowe et al., 2012). On the other side, it is predictable that 
the Sec14-PH module of NF1, which is relevant for phospholipid-binding (D'Angelo et 
al., 2006, Welti et al., 2007), is liable for NF1 membrane localisation and this way 
may reach high proximity to Ras. It is known that lipids like arachidonic acid and 
phosphatidic acid are negative regulators of the NF1 GAP activity, but no lipid was 
identified to stimulate the NF1 GAP activity and thereby switch off Ras (Tsai et al., 
1989, Tsai et al., 1990, Golubic et al., 1991, Han et al., 1991).  
Another mechanism to localise NF1 at the membrane has been described in 
neurons. Here the interaction of NF1 with syndecan, a transmembrane protein, has 
been supposed to facilitate NF1 translocation (Hsueh et al., 2001). For neuronal cells 
it has been further reported that an EGF-dependent PKC phosphorylation on NF1 
increases its association with the actin cytoskeleton and the NF1 GTPase activity 
(Mangoura et al., 2006). In addition, NF1 seems to link the Ras pathway with PKA-
associated signals, due to the binding of 14-3-3 protein to a PKA-dependent 
phosphorylation site which reduces NF1 GAP activity (Feng et al., 2004). Altogether, 
it is conceivable that in response to EGF a Rsk-mediated phosphorylation or lipid 
modification of NF1 can influence the NF1 localisation and accessibility to Ras.  
Vice versa, a translocation of Ras within the plasma membrane may also lead to the 
formation of a Ras/NF1 complex. In this context, studies have demonstrated that 
40% of Ras proteins are distributed to distinct micro- and nanoscale domains at the 
plasma membrane, and that the exact pattern of distribution has major impact on the 
downstream signalling capacity of Ras (Prior et al., 2003, Rotblat et al., 2004, 
Plowman and Hancock, 2005, Roy et al., 2005, Zhou and Hancock, 2015). Initial 
nanocluster assays without EGF show that MEK inactivation led to a marked 
increase in H-Ras nanoclustering. This observation indicated a role of MEK in Ras  
nanoorganisation. Ras nanocluster distribution after growth factor stimulation and its 
importance for MEK or Erk activity has never been addressed before.  
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It was only reported that B-Raf inhibition enhances clustering of K-Ras and N-Ras but 
not H-Ras with consequent enhancement of MEK-Erk activation. At least the 
demonstration that effectors other than Raf regulate Ras clustering is novel. 
However, a MEK-dependent nanocluster rearrangement to increase the Ras 
accessibility for NF1 to decline RasGTP level is straight forward. Unfortunately, the 
attempts to address changes in Ras nanoclustering after EGF stimulation did not 
reveal a possible regulation mechanism. In accordance, SLO permeabilised cells 
feature similar transient RasGTP level, even though cholesterol containing 
microdomains are destroyed and consequently Ras distribution is likely to be 
affected. 
 
 
 
Figure 29: Possible mechanisms to initialise the decline of RasGTP levels. 
1) Rsk directly activates NF1 via phosphorylation. 2) One or more unknown interacting proteins get 
engaged by Rsk and regulate NF1 GAP activity; here also NF1 interacting proteins like Spred or 
ubiquitin-dependent NF1 proteolysis play a role. 3) A NF1 independent mechanism describes a MAPK 
dependent Ras rearrangement after growth factor stimulation. 
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10.5 Combination of biological data and mathematic modelling 
Ras activation and subsequent desensitisation is controlled at multiple steps and 
several connected pathways that are simultaneously active. It was postulated that a 
cross-talk between the kinase Rsk and NF1 somehow leads to Ras deactivation after 
growth factor stimulation. It was attempted to link and confirm the obtained results, so 
computational modelling was realised in cooperation with Graham Ladds (University 
Cambridge) and Manuel A. Esparza-Franco (University of Warwick). 
One generated model was the so called GEF-only model which postulates that 
transient Ras activation mediated by RasGTP-dependent feedback inhibition of Sos 
requires high basal GAP activity. Previous simulations (Ozaki et al., 2005, Wolf et al., 
2007) and results emerged from the permeabilisation assay verified that assumption, 
since the intrinsic nucleotide exchange and GTP-hydrolysis rate of Ras compensate 
each other (Hennig et al., 2015). This implies that RasGTP levels would drop very 
slowly if Sos became inactivated in a background of null basal GAP activity. The 
finding that RasGTP levels were not increased in GAP diminished cells reveal that 
HeLa exhibit a low basal GAP activity. This observation further indicates that there 
might be a RasGTP driven pathway that turns on GAP activity after growth factor 
stimulation. The importance of GAP activity was further highlighted by the fact that 
GEF activity does not decay during Ras deactivation. Moreover, we could show that 
Ras deactivation was indeed MEK/Erk- and even Rsk-dependent, but not modulated 
by Sos as proposed before (Brightman and Fell, 2000, Cirit et al., 2010, Kamioka et 
al., 2010). 
To validate our assumption that a high GAP activity evokes the decline of RasGTP 
level, Manuel A. Esparza-Franco created two mathematical models based on our 
experimental data. We combined computational modelling with biochemical 
experiments to elucidate the dynamics of these feedback mechanisms. The 
modelling predicted fast changes of RasGTP levels at late time GEF/GAP blockade. 
In the 1st experiment the GAP activity was blocked by adding an Erk inhibitor late 
post-EGF stimulation and we observed an immediate rise in RasGTP levels due to 
the maintained high Sos activity. In the 2nd experiment an EGFR inhibitor was 
applied to the same late stimulation time point to block Sos activity. We observed a 
drop in RasGTP levels most likely due to continuous high GAP in the absence of 
GEF activity. At least we could confirm all predictions of the models in our cells and 
sum up all present findings in a revised minimal mathematical model that represent 
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transient Ras activation in the background of RasGTP-dependent GAP activation 
(Figure 30).  
 
Figure 30: Mathematical model describing the feedback stimulation of GAPs.  
Minimal mathematical model describing Ras activation/deactivation mediated by a positive feedback 
stimulation of RasGAP. Figure created by Manuel A. Esparza-Franco. 
Taken together, the findings indicate that Ras deactivation is not initiated by merely 
Sos inhibition. In addition to the involvement of Rsk in a feedback loop mediating Ras 
signal termination, we identified NF1 as the GAP species counteracting continuously 
high Sos activity (Figure 31). Furthermore, our data reveal for the first time a 
biochemical evidence for a role of the tumour suppressor NF1 controlling the growth 
factor-induced Ras activity. 
 
Figure 31: Schematic cartoon of the mechanism of Ras activation/deactivation.  
After EGF stimulation Sos promotes activation of Ras at the cellular membrane by facilitating 
exchange of GDP for GTP. Active Ras binds Raf and initiates the MAPK signalling. The termination of 
active Ras at late time stimulation point is caused by Rsk dependent feedback stimulation of NF1 in 
the background of prolonged Sos activation. 
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10.6 Clinical Relevance of Rsk dependent NF1 activation 
The tight control of Ras activation/deactivation is important in regulating cell growth. 
Gain of function mutations within the Ras pathway or the dysregulation of its 
connected negative regulators lead to various developmental disorders collectively 
termed RASopathies. These syndromes often reveal overlapping phenotypic features 
caused by moderate over-activation of MAPK signalling. Patients with such 
syndromes are predisposed to cancer (Simsek-Kiper et al., 2013). NF1 was identified 
more than 20 years ago as a large transcript disrupted in neurofibromatosis type I 
patients (Wallace et al., 1990). However the critical affected pathways involved in the 
pathogenesis of neurofibromatosis are still unknown. Various interacting factors like 
Spred proteins, ubiquitin, lipids and tubulin have been described but none of them 
seems to be causative for the disease progression (Bollag et al., 1993, Hsueh et al., 
2001, De Schepper et al., 2006, Stowe et al., 2012, Hollstein and Cichowski, 2013). 
In accordance with our experiments, Larribere et al. (Larribere et al., 2015) recently 
published that NF1 loss induces senescence during melanocyte differentiation as 
well as in patient derived cafe-au-lait macules.  
Interestingly, Stowe and colleagues postulated that the Legius syndrome, caused by 
SPRED1 mutation, and neurofibromatosis-1 might have some molecular 
mechanisms in common (Stowe et al., 2012). In our study we could not determine 
any functional link between Spred1 and NF1 in growth factor mediated signalling.  
But our data convincingly suggests that Rsk is able to induce NF1 activity in order to 
downregulate the RasGTP level in response to mitogen signalling. The data provide 
a rational explanation of the overlapping clinical manifestation of neurofibromatosis 
and the Coffin-Lowry syndrome, which is caused by mutations in RSK2 (Trivier et al., 
1996). The Coffin–Lowry syndrome is likewise associated with mental retardation as 
well as growth, cardiac and skeleton abnormalities (Delaunoy et al., 2006), partially 
reflecting pathophysiology of RASopathies. Interestingly, initial diagnoses of Noonan 
syndrome had to be revised to Coffin-Lowry syndrome or neurofibromatosis-1 (Chen 
et al., 2014) Different cell types may simply invoke various components of the MAPK 
pathway reflecting distinct features of each disorder. Finally, it is likely that the RSK2 
gene is a new addendum to the RASopathy genes, for which we offer new 
mechanistic insight. 
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The clinical use of Erk and MEK inhibitors in anti-cancer therapy is often depending 
on combinatorial treatment with other relevant drugs (Poulikakos and Solit, 2011, 
Hatzivassiliou et al., 2012, Sun et al., 2014). This is due to reactivation of the Raf-Erk 
pathway leading to resistance to Erk or MEK inhibitor treatment alone (Sanchez-
Laorden et al., 2014). Based on our data set, it can be assumed that MEK inhibition 
based anti-cancer treatment leads to reduced NF1 activity followed by prolonged and 
enhanced Ras activation. This in turn favours the development of drug resistance 
and aggravation of the disease for example elevated tumour formation. Our data 
provide comprehensive explanations how MEK inhibition as a single agent treatment 
represents a viable therapy for Neurofibromatosis patients, which was shown before 
by other groups (Chang et al., 2013, Jessen et al., 2013).  
10.7 Concluding remarks 
The cellular response of the growth factor induced Ras-MAPK signalling depends on 
the duration of the Ras activity. Meaning, Ras proteins act as a critical switch and 
determine the cell’s fate. Numerous studies showed that a transient Ras activation 
mediates cell proliferation, whereas prolonged activation of the Ras/Erk pathway 
drives the cells in senescence (Serrano et al., 1997, Lee et al., 1999) or shifts the 
balance towards differentiation (Qui and Green, 1992, Traverse et al., 1992, Halfar et 
al., 2001). In accordance, NF1 loss promotes senescence in cells to hold back 
tumorigenesis by preventing progression of benign tumours to malignancy 
(McGillicuddy et al., 2009, Larribere et al., 2015). The complexity of this cellular 
behaviour requires a tight regulation of Ras activity. In our study we provide the 
experimental basis to convincingly propose a central role of the Ras negative 
regulator GAP namely NF1 instead of GEFs in playing a central role in Ras 
deactivation. We observed that the Ras signalling pathway features a more complex 
regulatory mechanism in terms of temporal Ras activity modulation which is 
coordinated through partially unknown feedback loops, specific cross talks of certain 
mediators and scaffold proteins. In this respect it is important to note that kinetics of 
the Ras activity depend on the cell type and specific kind of stimulus. At least in our 
EGF stimulated cells we showed that Ras initiate its own deactivation mechanism via 
feedback activation of NF1 possibly  through Rsk. Taken together, these data provide 
the first evidence that NF1 activity is regulated by growth factor signalling, although 
the exact biochemical process linking Rsk and NF1 activation remains an enigma.  
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The large size of the tumour suppressor NF1 and the technically limitations in 
handling NF1 plasmids have all contributed to the hurdles that still make the research 
of NF1 function and its precise role in controlling Ras signalling pathways 
experimentally challenging. An important goal of the next few years will be to better 
understand the relevance of possible NF1 interaction partners such as Spred 
proteins or to identify new NF1 interaction partners. For this purpose, studies with 
full-length NF1 are necessary because most biochemical studies have been 
performed with fragments comprising the catalytic domains of NF1. Future work 
should also resolve the influence of potential Rsk- or Erk-dependent NF1 
phosphorylation. Additional efforts are needed to entirely understand the role of NF1 
that may differ depending on the cell type specific features. Further it is of high 
relevance to improve therapeutic options of patients suffering from RASopathies that 
is based on the complete knowledge about the complex Ras signalling network. 
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